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  Objective: Cardiovascular risks (CVR) such as hypertension and hyperlipidemia 
play a critical role in the emergence of dementia syndromes. Medication to treat CVR 
may not obviate downstream risk for cognitive change. Methods: To examine the relation 
between history of treatment with medications to treat CVR and cognitive outcomes, 
participants were seen at time points ~7 years apart, completed neuropsychological 
evaluations, assessed for history of treatment with medication associated with 
hypertension and hyperlipidemia as indicators of CVR, and classified into 3 groups: Not 
Treated, Inconsistently Treated, and Consistently Treated. Regression models associating 
neuropsychological outcome measures of cognition and CVR were explored and refined 
within a “test dataset,” and analyses were replicated using an independent “validation 
dataset.” Result: Most outcome measures were not significant, including episodic 
memory and executive tests. A main effect was found for hypertension for the 
Similarities subtest and the Digit Symbol Test; participants with no hypertension 
treatment history obtained better scores compared to other groups. While some measures 
were sensitive to impairment, MRI parameters were not associated with CVR indicators. 
Conclusion: Between group differences on outcome measures of cognition were 
detectable in the presence of well-controlled blood pressure, indicating that downstream 
cognitive consequences persist in the presence of intervention for hypertension.  
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 Cognitive decline associated with dementia such as Alzheimer’s disease (AD) is a 
leading concern among older and aging populations, with projections indicating that as 
many as 14 million Americans may be affected by AD by the year 2050 (Alzheimer’s 
Association, 2019).  It is now well-known that vascular disease, including alterations in 
the blood-brain barrier (Emrani et al., 2020; Nation et al., 2019) and cardiovascular (CV) 
risks such as hypertension and elevated lipids, plays a role in the emergence of AD.  
Indeed, these CV risks, well-known to be associated with stroke, have emerged as 
significant risk factors for AD (Iulita & Girouard, 2017; Poels, Ikram et al., 2012).  It is 
therefore increasingly important that CV risk factors be closely observed within the 
context of dementia risk and as a possible avenue for prevention and intervention of 
dementia onset (Knopman et al., 2018).  
Longitudinal research has demonstrated that the incidence of dementia declines 
when CV and cerebrovascular disease are controlled (Satizabal, Beiser, & Seshadri, 
2016; Schrijvers et al., 2012; Wu et al., 2017).  It is increasingly evident that dementia 
arising from mixed aetiologies involving proteins such as amyloid and tau, in addition to 
vascular disease, is the most common pathway for insidious onset dementia (Emrani et 
al., 2020; Sweeney et al., 2019).  Common CV risk factors include hypertension, 
hyperlipidemia, diabetes, smoking status and history, obesity, alcohol consumption, 
arterial stiffness and pulse pressure, atrial fibrillation, diet, and body mass index (BMI) 
score; as well as genetic vulnerabilities, including apolipoprotein epsilon 4 (APOE4) 
status (Institute of Medicine, 2015).  
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Community-Based Longitudinal Studies 
The Framingham Heart Study (FHS) is a multigenerational, longitudinal 
community study of CV health and cognition in a primarily white population recruited 
from the Massachusetts town of Framingham.  The original FHS cohort consisted of 
5,209 participants first recruited in 1948.  At the time of enrollment, the mean age was 44 
years (range 28–62 years), 55% were female, the majority were white and of middle 
socioeconomic class.  Participants returned for regular exam cycles roughly three to five 
years apart.   
Research from the FHS has linked cognitive impairment with CV risk factors 
such as hypertension (M. F. Elias, Wolf, D’Agostino, Cobb, & White, 1993; Farmer et 
al., 1987, 1990).  Studies employing the Framingham Stroke Risk Profile (Wolf, 
D’Agostino, Belanger, & Kannel, 1991), a composite measure of stroke risk, have 
established and supported that CV risk factors contribute not just to stroke risk, but also 
insidious onset dementia. CV risk factors are also associated with smaller cerebral brain 
volume and poorer performance on tests measuring executive function, visuospatial 
processing, attention, planning and psychomotor performance (Seshadri et al., 2004).  P. 
K. Elias, Elias, D’Agostino, Sullivan, & Wolf (2005) also found that elevated total 
cholesterol was associated with declining performance on measures of 
attention/concentration, abstract reasoning, and verbal fluency.  In another study, M. F. 
Elias, Elias, Sullivan, Wolf, & D’Agostino (2003) showed the negative association of 
hypertension on immediate and delayed visual and auditory episodic memory in men, but 
not women.  For male participants, the relation was compounded by obesity.   
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Research from the Rotterdam study, a similarly designed, community-based 
longitudinal epidemiological study, likewise pointed to an association between CV health 
and cognition, finding reduced cortical gray matter thickness on magnetic resonance 
imaging (MRI) to be positively associated with elevated diastolic blood pressure and 
higher HDL cholesterol levels (van Velsen et al., 2013).  The Rotterdam study has also 
been a source of support for the connection between blood-brain barrier integrity and CV 
health, as demonstrated in a study by Wieberdink and colleagues (2011) that found 
hypotriglyceridemia increased the risk for intracerebral hemorrhage and infratentorial 
cerebral microbleeds.  White matter lesions have also been reported to be more common 
among participants with uncontrolled hypertension (Poels, Zaccai, et al., 2012). 
What is interesting about past research is the nonlinear relation between CV risk 
factors like blood pressure, triglycerides and cholesterol, and cognitive and 
neuroanatomical outcomes, as negative outcomes are associated with falling above or 
below an ideal range for risk factor measures.  In addition, the age of the population 
being considered is important when interpreting CV risk and outcomes, with some 
research indicating that age modifies the relation of CV risk on cognition and mortality 
risk (Beckett et al., 2008; Blom et al., 2013).  Comorbidity involving multiple CV risk 
factors increases risk for emergent dementia.  In addition to diabetes (van Velsen et al., 
2013), other CV factors including homocysteine levels (Lu et al., 2019), sex assigned at 
birth (Matthews et al., 2016; Satizabal et al., 2016), smoking status, and BMI (Dregan, 
Stewart, & Gulliford, 2013) can compound the extent to which cognitive abilities are 
negatively impacted.  To better reflect the relations among risk factors, composite 
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measures such as the Framingham Stroke Risk Profile (Wolf et al., 1991) have been 
developed.  
Keeping these factors in mind, it should not be neglected that hypertension and 
hyperlipidemia are generally closely monitored and controlled.  Thus, the chosen method 
for intervention may further complicate the picture when trying to understand the extent 
these leading CV risks may signal vulnerability to cognitive decline.  As such, the mere 
fact of being treated for a condition is often considered synonymous with having the 
condition (Institute of Medicine, 2015).  
Hypertension and Treatment 
For most studies, a participant is considered to be hypertensive when average 
systolic blood pressure is at or above 140 mmHg, diastolic blood pressure is 90 mmHg or 
above, or if an individual is receiving antihypertensive medications (Institute of 
Medicine, 2015).  Six commonly prescribed drug classes of medication for 
antihypertensive treatment are thiazides, beta-blockers, alpha-blockers, calcium channel 
blockers, angiotensin converting enzyme (ACE) inhibitors, and angiotensin-II receptor 
blockers (Wright, Musini, & Gill, 2018). 
Reduction of stroke risk is the most obvious cognitive benefit of well-managed 
blood pressure, and is well-associated with antihypertensive drug use (Wright et al., 
2018).  Additionally, robust longitudinal data supports a relation between blood pressure 
and cognitive decline (M. F. Elias, Goodell, & Dore, 2012; Etgen, Sander, Bickel, & 
Förstl, 2011; Unverzagt et al., 2011), with more consistent associations observed for 
midlife hypertension than later-life.  Lamar and colleagues (2020) reported a negative 
association between decision making and blood pressure among older individuals. 
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A systemic review by Walker, Power, & Gottesman (2017) strongly supports the 
relation between age, duration/chronicity of hypertension, and cognitive decline, 
emphasizing in particular that late-life cognitive decline and dementia was consistently 
related to elevated hypertension measures during mid-life.  The collective research of 
early- and mid-life indicators of hypertension corroborates the evidence from longitudinal 
studies that the downstream consequences of hypertension on brain anatomy and 
cognitive functioning are cumulative.  Some have gone so far as to argue that studies of 
interventions in later life may underestimate the protective ability of antihypertensive 
medications to affect cognition (Institute of Medicine, 2015; Qiu, Winblad, & Fratiglioni, 
2005).  Nonetheless, the ability for antihypertensive drugs to curb cognitive 
consequences of hypertension remains uncertain.  Antihypertensive medications may 
have some cognitive protective effects (Rouch et al., 2015; Streit, Poortvliet, Den Elzen, 
Blom, & Gussekloo, 2019), but studies frequently return inconclusive findings (Chang-
Quan et al., 2011; Ligthart & Press, 2010; van Dalen, Moll van Charante, van Gool, & 
Richard, 2019).   
Inconsistent findings, as reported in Rouch et al., (2015) and Staessen et al., 
(2011), are likely indicative of differences among antihypertensive drug classes with 
respect to cognition.  For example, Peters (2019) found that treatment with calcium-
channel blockers may have no benefits for preventing cognitive decline.  Adherence, 
duration of treatment, and dosage level are other likely causes of varying findings for 





Hyperlipidemia and Treatment 
Hyperlipidemia is characterized by a high level of blood lipids, including 
triglycerides and cholesterol (Crawford et al., 2010), and has been implicated in cognitive 
decline (Etgen et al., 2011).  Fifty percent of older Americans are estimated to have 
hyperlipidemia (Crawford et al., 2010).  Hyperlipidemia may be a stronger risk factor for 
midlife cognitive decline than later life (Reynolds, Gatz, Prince, Berg, & Pedersen, 2010; 
Van Vliet, 2012).  Consequently, as with hypertension, early life interventions may 
demonstrate greater protective effects than mid- and late-life interventions.  For example, 
interventions with B vitamins, including niacin, in young adulthood was associated with 
better cognitive function outcomes, particularly psychomotor speed as measured with the 
Digit Symbol Substitution test and executive function measured with the Stroop Test 
(Qin et al., 2017). 
Intervention with medication may involve a variety of medication types with 
differing mechanisms of action, including statins; non-statin drugs such as B-vitamins, 
omega-3 supplements, and anti-triglycerides; or a combination of all.  Statin and non-
statin drugs are often handled separately in literature when discussing cognitive 
consequences of treating hyperlipidemia with medication.  Statins are the preferred 
treatment unless patients are poor responders to statin therapy, though non-statins may 
also be combined with statins if indicated (Catapano et al., 2016). 
There is inconclusive evidence that hyperlipidemia treatments have a significant 
impact on cognitive aging (Catapano et al., 2016; Gauthier & Massicotte, 2015; Institute 
of Medicine, 2015).  Although statins have previously been associated with potential 
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memory loss (FDA, 2012), these results have not been consistently upheld (McGuinness, 
Todd, Passmore, & Bullock, 2009; Ong et al., 2018; Richardson et al., 2013).  
Differences in methodology and design may be partly to blame for the lack of 
consensus over the past two decades of research.  In a recent review, Tan and colleagues 
(2019) suggest that randomized, double-blind, placebo-controlled studies that returned 
negative findings related to statins and cognition were generally underpowered, differed 
in participant demographics, and used a variety of cognitive measures differing from 
measures used in studies reporting significant associations between statins and cognition. 
Another explanation that may underlie the inconsistent findings associating 
cognition and hyperlipidemia treatment is the differences in the mechanisms of action 
among statin-type drugs.  Highly lipophilic statins (atorvastatin, simvastatin, lovastatin, 
fluvastatin, cerivastatin, and pitavastatin) more easily cross the blood-brain barrier than 
hydrophilic statins (pravastatin and rosuvastatin; Schachter, 2005).  In most cases of 
statin-related cognitive impairment, the association has been with the more lipophilic 
statins (Rojas-Fernandez & Cameron, 2012; Wagstaff, Mitton, Arvik, & Doraiswamy, 
2003). 
Previous studies from the FHS have been mixed.  Tan and colleagues (2003) 
found no relation between cholesterol measures and AD among first generation study 
participants.  Examining the same cohort, Silverman and Schmeidler (2018) observed 
that non-use of statins was associated with greater risk for cognitive decline as measured 
by performance below 25 on the Mini-Mental States Exam (MMSE).  However, the 
relation between mid-life hyperlipidemia indicators and later life cognition was 
attenuated by age at follow up, with an inflection point for individuals older than 85.  In 
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these oldest participants, hyperlipidemia risk factors were inversely related with risk for 
dementia.  This may reflect a survivorship bias, with the oldest of participants reflecting a 
subset of “protected” individuals who remain cognitively intact despite the presence of 
risk factors.  The reversal of the risk association may also be a consequence of having too 
few time points to model a quadratic relation between cholesterol and cognition.  
Treatment of hyperlipidemia with statins is considered safe and beneficial for 
those who respond to them (Adhyaru & Jacobson, 2018; Catapano et al., 2016); however, 
there remains no consensus on cognition.  Fibrate use, a non-statin alternative, is 
associated with poor visual memory as assessed with the Benton Visual Retention Test 
for women, but not for men, over a 7-year period (Ancelin et al., 2012).  Other domains 
of cognition that were tested, including processing speed as measured by the Trail 
Making Tests, overall cognition as measured by the MMSE, and verbal fluency/semantic 
access as measured by Isaacs Set test, were not significant.  
Combined treatment with statins and non-statins is common, but no more 
associated with consistent cognitive findings than either treatment type individually.  For 
example, lipid-modifying treatment combining statins and ezetimibe can reduce the loss 
of cerebral volume related to atrial fibrillation, particularly in the medial temporal lobe 
(Lappegård et al., 2013; Tendolkar et al., 2012).  This is hypothesized to be related to the 
reduction in the effects of inflammation on cognition. 
The Current Study 
In summary, the relation between hyperlipidemia, hypertension, and downstream 
decline in cognitive abilities and neural anatomical function is strongly indicated in the 
literature, but not well understood.  In particular, whether interventions that are beneficial 
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for CV risk are associated with any measurable benefits on cognitive performances 
remains an open question.  The near-universal availability of treatment for individuals 
with CV risk is an important consideration when attempting to understand cognitive 
vulnerability.   
The current study was designed to address these questions through an analysis of 
data available from the FHS utilizing a Cumulative Analytic Strategy (Fife & Rodgers, 
2019) involving Rough Confirmatory Data Analysis (CDA) into a Strict CDA approach 
using a holdout sample.  This approach was intended to articulate the relation between 
treatment history for CV risk factors and cognitive outcomes.  In particular, the current 
research intended to answer the following question - Is there a negative outcome for 
cognition and brain anatomy associated with whether one is identified as treated for CV 
risk; despite the fact that treated indicators for CV risks are generally within an 
acceptable range?  Put another way, does generally successful treatment of CV risks 
obviate downstream neuropsychological impairment and putative neuroanatomic 
compromise as measured with MRI regions of interest? 
Study Aims 
This central question was addressed through four aims: 1.) Do adults who endorse 
a history of treatment for hypertension or hyperlipidemia show worse neuropsychological 
(NP) outcomes than participants who do not?  2.)  As well, do adults who endorse a 
comorbidity of treatment for hypertension and hyperlipidemia show worse 
neuropsychological outcomes than those participants without comorbidity?  3.)  Recent 
research suggests that visual episodic memory measures, as compared to verbal episodic 
memory tests, may be more sensitive to emergent decline (Wasserman et al., 2019).  
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Thus, the current research assessed for modality-associated sensitivity within episodic 
memory testing relating to treatment history/combination of treatment histories.  4.)  Are 
relations among treatment history and neuroanatomy measured using MRI scans 
consistent with findings from neuropsychology in Aim 1? 
Hypotheses 
Hypothesis 1 was constructed to address Study Aims 1, 2 and 3.  Hypothesis 2 
addresses Study Aim 4. 
Hypothesis 1a.  Poorer NP outcomes were expected for individuals with 
treatment history than individuals with less or without treatment history across NP 
domains known to be susceptible to controlled, but nonetheless chronic, CV illness.  
Those with a consistent history of treatment (Consistent Treatment Group) for 
hypertension were expected to perform more poorly on these tasks than participants with 
inconsistent history (Inconsistent Treatment Group) of treatment or no history (No 
Treatment Group).  Having some history (i.e., Inconsistent Treatment Group) was 
expected to be associated with worse performance on measures than having no history 
(No Treatment Group).  The same pattern was expected for treatment history for 
hyperlipidemia.  
Hypothesis 1b. CV risk factors were expected to have a compounding impact 
when multiple CV risks are present.  If an interaction were present, it was expected that 
NP measure performance would decline inversely with greater degree of treatment 
history for each CV risk factor.  Because of the uncertainty in the existing literature 
surrounding these relations, observed effect sizes related to Hypotheses 1a and 1b were 
reported; however, interpretation of the results of analysis was hedged to consider the 
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clinical value of small effect sizes and the provisional nature of results obtained through a 
Rough CDA paradigm (Fife & Rodgers, 2019).  
Hypothesis 1c.  In the presence of significant findings for episodic memory, 
delayed recall on a visual episodic memory test (WMS-Visual Reproduction) was 
expected to be more sensitive to cognitive impairment, and therefore would yield a larger 
effect size, than performance obtained from a verbal episodic memory test (WMS- 
Logical Memory). A meaningfully larger effect size would explain at least 1% additional 
variance. 
Hypothesis 2.  It was expected that there would be more gray matter volume in 
the never treated groups for both lipids and hypertension compared to the consistently 
treated groups.  The inconsistently treated group was expected to fall between the mean 







Sample & Demographics 
Data for the present study, including participant medication history, CV measures, 
and NP test performance, were obtained from the FHS through a research contract with 
Rowan University School of Osteopathic Medicine (Rowan SOM; IRB protocol number: 
2016001189).  The so-called “offspring cohort” was recruited in 1971, consisting of 
5,124 offspring of the original cohort and their spouses.  At enrollment, the mean age was 
36 years (range 5–70 years), 52% were women.  As with the original cohort, follow-up 
exams were completed in cycles held approximately 5 years apart, with most variance in 
scheduling related to participant availability.  In addition to a “core exam” focused on CV 
factors, FHS participants were invited to participate in ancillary study exams.  
Recruitment for an on-going study of cognition, dementia, and NP performance for the 
Offspring Cohort began in the 7th core exam cycle.  More information on the FHS 
cohorts and exam cycles can be found in Ang, Joshi, & Au (2020). 
Data received from FHS included medical, CV, cerebrovascular, NP, 
psychological, and mortality data for all Framingham cohorts, as well as on-going and 
concluded sub-studies for other heart health-related topics such as stroke risk, pregnancy, 
bone density, diabetes, and radiological imaging.  For data security, all datasets were 
received without identifying information such as names and birthdays.  Measures of CV 
health and NP performance were collated and organized to create a sample of 1,160 
participants who had consistently participated in the three most recent exam cycles 
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(Exams 7, 8 and 9) of the FHS Offspring Cohort; and who also attended separate, 
corresponding NP evaluations.   
Of the 1,160 participants identified for the current research, 44 participants were 
determined to have evidence of stroke history or dementia and were excluded.  Of the 
1,116 remaining participants, 56 participants did not have medication use data at both 
exam 8 and exam 9, and were also excluded.  The remaining 1,060 participants formed 
the final study sample.  Of those who met criteria for study inclusion, a subsample (n = 
823) had also contributed MRI data concurrent with their NP evaluation.  Demographic 
information for the overall and MRI samples are available in Table 1. 
 
Table 1 
Demographics for Total Sample and MRI Subsample 
 Total Sample (n=1060)  MRI Subsample (n=823) 
Age (years) 
Mean (sd) 
 71.45 (8.03)    70.89 (7.77)  
Years of 
Education 
       
 <12 years 28 2.6%  <12 years 19 2.3% 
 High School 
Graduate 





307 29%  Some College 228 27.7% 
 College 
Graduate 
513 48.4%  College 
Graduate 
418 50.8% 
Female Sex at 
Birth (%Female) 




 28.35 (5.37)    28.00 (5.08)  
 
 
Cardiovascular Risk and Measurement of Treatment History 
The CV features of interest were whether a patient was treated for 1.) 
hypertension, and 2.)  lipids, at exams 8 and 9.  This information was expressed as two 
categorical variables with three levels each: 1.)  Never Treated, did not endorse treatment 
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at exam 8 or exam 9; 2.) Inconsistently Treated, endorsed treatment at only 1 time point; 
and 3.) Consistently Treated, endorsed treatment at both exam 8 and 9.  To determine for 
which level of treatment participants met criteria, two approaches were considered: 
whether participants reported treatment history for hypertension and lipids as part of a 
self-report interview during the cycle core exam, and whether participants endorsed 
taking medication at core exam cycle 8 and 9 that treats hypertension and/or 
hyperlipidemia. 
While both approaches rely on self-report, cross tabulation of both grouping 
criteria indicated that participant knowledge of medication purpose was a limiting factor 
on the reliability of reported treatment history (see Table 2 & 3).  Participants 
occasionally endorsed no treatment when being treated with medication, as well as 
treatment when not being treated with medication, although this was less frequent and 
may reflect the heterogeneity of treatment approaches for CV risk factors in addition to 
medication, such as diet and exercise.  
 
Table 2 
Comparison of Self-Report and Medication-Endorsed Hypertension Treatment History 
  Self-Report History of Hypertension Total 








Never Treated 372 1 1 374 
Inconsistently 
Treated 
38 124 7 169 
Consistently 
Treated 
28 38 450 516 







Comparison of Self-Report and Medication-Endorsed Hyperlipidemia Treatment History 
  Self-Report History of Hyperlipidemia Total 








Never Treated 320 0 0 320 
Inconsistently 
Treated 
126 126 2 254 
Consistently 
Treated 
30 38 417 485 
Total  476 164 419 1059 
 
 
Early designs of the study relied on the self-report approach; however, 
preliminary analysis indicated that study participants might have anywhere between a 
well-developed understanding of their medical treatment or a poor grasp on it.  While 
interesting within the context of treatment and adherence, FHS is a community study of 
CV health and cognition, and these self-report items are informed by the individual's 
understanding of their medical history.  As a consequence, the self-report method for 
grouping participants is less reliable than the approach based on endorsed medication 
history. Groups were therefore based on whether an individual endorsed using an 
antihypertensive or lipid-modifying agent at exam 8 and/or exam 9. 
  For the total sample, groups for both treatment history for hypertension 
(TxHxHypertension) and treatment history for hyperlipidemia (TxHxLipids) significantly 
differed in age (TxHxHypertension: F[2,1057] = 60.459, p < .001; TxHxLipids: 
F[2,1057] = 24.136 p < .001), education (TxHxHypertension: F[2,1057] = 5.010, p < .01; 
TxHxLipids: F[2,1057] = 3.576, p < .05), and sex at birth (TxHxHypertension: F[2,1057] 
= 14.919, p < .001; TxHxLipids: F[2,1057] = 6.139, p < .002).  For the MRI subsample, 
groups differed for age (TxHxHypertension: F[2,820] = 51.303, p < .001; TxHxLipids: 
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F[2,820] = 18.742, p < 0.001), education (TxHxHypertension: F[2,820] = 3.815 , p < .05; 
TxHxLipids: F[2,820] = 3.421, p < .05), and sex at birth (TxHxHypertension: F[2,820] = 
9.667, p < .001; TxHxLipids: F[2,820] = 4.143, p < .05). Group distributions and 




Demographics for Hypertension Treatment Groups in the Total Sample and MRI Subsample 
 Total Sample (n=1060)   MRI Subsample (n=823) 




















70.41 (7.33) 74.01 (7.64)    67.86 
(7.41) 
70.28 (7.26) 73.52 (7.31) 
Education   3.34 
(0.85) 
3.23 (0.86) 3.15 (0.86)    3.37 
(0.82) 
3.26 (0.85) 3.19 (0.86) 
 <12 
years 




78 38 126   High 
School 
Graduate 
64 29 88 
 Some 
College 
76 41 87   Some 
College 
61 29 100 
 College 
Graduate 
214 87 230   College 
Graduate 






100 (58.8%) 260 (50.3%)    202 
(65.6%) 








28.31 (5.42) 29.58 (5.67)    26.76 
(4.50) 






Demographics for Hyperlipidemia Treatment Groups in the Total Sample and MRI Subsample 
 Total Sample (n=1060)  MRI Subsample (n=823) 




















70.76 (7.64) 73.20 (7.53)   69.02 
(8.24) 
70.13 (7.43) 72.66 (7.22) 
Education   3.25 
(0.83) 
3.34 (0.84) 3.16 (0.88)   3.26(0.83) 3.40 (0.81) 3.21 (0.87) 
 <12 
years 
4 3 19  <12 
years 




72 53 117  High 
School 
Graduate 
59 37 85 
 Some 
College 
78 60 123  Some 
College 
63 41 86 
 College 
Graduate 
166 139 226  College 
Graduate 







162 (63.5%) 254 (52.4%)   158 
(60.3%) 








28.52 (5.63) 28.95 (5.23)   27.23 
(5.00) 
28.60 (5.74) 28.75 (4.91) 
 
 
The following antihypertensive drug classes were considered indicative of 
antihypertensive treatment for the purposes of this study (Wright et al., 2018): thiazides, 
beta-blockers, alpha-blockers, calcium channel blockers, ACE inhibitors, and angiotensin 
II receptor blockers.  Medications considered lipid-modifying agents included statin and 
non-statin drugs (Catapano et al., 2016).  The following were considered non-statins:  
Bile Acid Sequestrants, a medication that reduces the volume of bile acid in the blood 
stream and contributes to the synthesis of cholesterol by the liver; Fibrates, which interact 
with lipoprotein metabolism; Omega-3 fatty acids, mainly taken to lower triglyceride 
levels and indirectly reduce LDL concentration; Ezetimibe, a medication that targets lipid 
absorption in the intestines and is typically paired with a statin; Niacin, a B vitamin 
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influencing the production of blood fat and derived from nicotinic acid; and PCSK9 
Inhibitors, a newer statin-alternative prescribed as a preventative for CV disease through 
inhibiting the PCSK9 protein involved in plasma LDL concentration.  Of these 
interventions, only use of PCSK9 Inhibitors was not endorsed by any participants. 
While the use of medication history was expected to be a more reliable indicator 
of group membership than participant-endorsed treatment history, this approach was not 
without limitations.  Firstly, it did not control for any instances of polypharmacy; that is, 
the use of multiple medications to treat a particular medical issue or set of issues, and the 
possibility of drug interactions that may affect efficacy.  In this same vein, changes in 
medication class/specific medication between exams was not monitored with this 
approach.  Given that changes in a treatment regimen are likely to be reactive and based 
on how well the individual responds to treatment, adjustments to intervention with 
medication may obscure some of the relation between CV risk and cognitive 
performance.  Secondly, being prescribed a medication does not guarantee adherence.  
Participants may discontinue medication without consulting a physician due to undesired 
side-effects, or present with low adherence due physical and/or cognitive limitations, or 
psychological conditions such as depression (Hennein et al., 2018).  Individuals taking a 
combination of statins and non-statins are more likely to discontinue due to adverse 
events compared to statins alone (Chaiyasothi et al., 2019).  Also, a participant endorsing 
treatment with a medication does not guarantee that the medication is being taking 
according to instruction.  Lastly, other health and CV factors, such as type 2 diabetes 
status, may modify responding to antihypertensives and lipid modifying agents (Institute 
of Medicine, 2015). 
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Neuropsychological Measures of Cognition 
 The FHS neuropsychological protocol of tests was a comprehensive, 1-hour to 
1.5-hour evaluation of multiple domains of cognition and had been updated at several 
times since its initial administration (Ang et al., 2020; Au, Piers, & Devine, 2017).  The 
full protocol of tests, as of the 9th exam cycle of the Offspring Cohort, consisted of 23 
distinct tasks adapted in part or in whole from widely-used published tests and protocols.  
Due to the high number of available NP measures within the FHS dataset, a priori 
considerations were used to select an exemplar set of six NP tests that could each be 
related to particular domains of cognition; either Executive Control/ Processing Speed, 
Naming/Lexical Access, or Episodic Memory.  These considerations included how well-
associated the selected task was with the intended domain and the relative sensitivity of 
these tasks to CV aetiologies of cognitive impairment (Frances, Sandra, & Lucy, 2016).  
Selected Neuropsychological Tasks and Domains 
Processing speed. This domain was assessed with the Verbal Fluency test 
(Spreen & Strauss, 1990) and the Digit-Symbol Coding subtest from the Wechsler Adult 
Intelligence Scales-Revised (WAIS-R; Wechsler, 1981). 
Naming/ lexical access. Language and lexical access were assessed with a 30-
item version of the Boston Naming Test (BNT; Kaplan, Goodglass, & Weintraub, 1983) 
and the Similarities subtest from the WAIS-R (Wechsler, 1981). 
Episodic memory. Because of previous research indicating differences in the 
relative sensitivity of visual and auditory episodic memory to cognitive change 
(Wasserman et al., 2019), both a visual and an auditory task of episodic memory were 
included. The Visual Reproduction task – delayed free recall from the Weschler Memory 
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Scale (WMS; Wechsler, 1945) was used to assess visual episodic memory and the WMS 
Logical Memory task – delayed free recall (Wechsler, 1945) was selected to assess 
auditory episodic memory. 
Considerations for Memory Measures 
Recognition memory tasks were considered in place of delayed free recall tasks, 
but were discarded due to the truncated range of the recognition measure used for Visual 
Reproduction, which had a maximum possible score of four and a minimum possible 
score of zero.  This would have negatively affected the ability to make relative 
comparisons to verbal memory recognition, which had twelve response items.   
Regression-Based Normative Approach 
Generally speaking, normed, standardized scores are preferable to raw 
performance measures when interpreting NP data.  Raw data do not allow for direct 
comparisons between different measurement scales.  For example, some tasks were based 
on accuracy, while others were based on performance speed.  Some allowed for “partial” 
accuracy or a correct response after a cue, while others did not.  Critically, correlated 
factors such as age, sex at birth, race, and years of education are well-known to affect 
performance on NP measures apart from differences related to the theorized associated 
domains of cognition (Marchant et al., 2013; Matthews et al., 2016; Ritchie, Artero, & 
Touchon, 2001; Satizabal et al., 2016; Schmand, Jonker, Hooijer, & Lindeboom, 1996).  
Traditional norms were not available for any NP measures used in this study due 
to FHS using older versions of tests that were normed in a different generation and due to 
the participant cohort being older than the upper limits of the original norms.  
Regression-based norms (RBN) were employed to address this limitation.  RBN is a 
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method in which demographic covariates are regressed against the centralized mean 
performance of a cognitively healthy subsample in order to yield beta weights for the 
covariates (Duff & Ramezani, 2015; Shirk et al., 2011).  These beta weights allowed for 
calculating an individual’s predicted performance on a measure given their age, 
education, and sex at birth.  These predicted scores provided a normative basis from 
which standardized scores for the entire sample could be calculated. 
While valuable when employed appropriately, RBNs are not a panacea for 
obtaining norms in understudied populations or populations who otherwise lack 
published norms. Fastenau (1998) demonstrated that RBNs are biased towards false 
negatives when the reference sample is overly small; however, RBNs may be more 
practical to obtain for an appropriately-sized sample than comparative observation-based 
norms (Oosterhuis, van der Ark, & Sijtsma, 2016).  Several studies have demonstrated 
the utility of RBN approaches in NP research (Beeri et al., 2006; Cavaco et al., 2013; 
Cysique et al., 2012; Heaton, Avitable, Grant, & Matthews, 1999; Shirk et al., 2011).  
RBNs also have the added benefit of modeling demographic information continuously, as 
opposed to traditional normed scores that frequently convert continuous data to discrete 
scaled scores (Lenhard, Lenhard, Suggate, & Segerer, 2018). 
For the present study, RBNs were constructed by identifying a subsample of 
cognitively healthy participants within the general purpose sample of n = 1,116 without 
likely dementia concern or cognitive impairment from stroke.  This healthy subsample 
consisted of n = 619 participants who consistently scored greater than 27 out of 30 on the 
Mini Mental Status Examination (MMSE) across five exam cycles.  This criterion was 
22 
 
employed to optimize the sensitivity of the MMSE to detect cognitive impairment 
(O’Bryant et al., 2008; Spering et al., 2012).   
Step 1.  While MMSE performance was used to increase the likelihood of 
identifying a cognitively healthy subsample, each NP task for this group was screened for 
outliers, defined as scores falling outside the range of - 3.29 ≤ z ≤ +3.29 (Tabachnick & 
Fidell, 2013), in order to ensure both 1.) a normal distribution of scores and 2.) that all 
individuals included reflected the intended cognitively healthy subsample.  Of the NP 
measures of interest for this study, outliers were found for only the BNT (n = 1).  
Extreme values were treated as missing, consistent with Tabachnick & Fidell (2013), 
because the extreme standardized score (z = -6.91) indicated that the individual’s 
performance was not consistent with other individuals believed to be cognitively healthy.  
Step 2.  Polynomial relations for age and education were tested to see if effect 
size from regression suggested important curvilinear relations for cubic and quadratic 
terms.  Quadratic relations were found for education and BNT, education and 
Similarities, age and BNT, and age and Logical Memory delayed free recall.  A cubic 
association was found for age and the Digit Symbol Coding subtest.  Associations 
without significant polynomial relations were treated as linear. 
Step 3.  Regression analyses were run adjusting for age, education and sex at 
birth, and including polynomial terms where indicated by assumption testing, to obtain 
coefficients and standard error of the estimate.  Predicted scores were calculated using 
coefficients from these regressions.  Z-scores were computed from the difference 
between actual and predicted scores divided by the standard error of the estimate.  Of the 
619 subjects from the cognitively healthy subsample of the original 1,116 participants in 
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NP exams 7, 8 and 9, there were 584 “normal” participants who were included in the 
current study sample after study-specific exclusion criteria previously described (i.e., 
without stroke or dementia, with medication history data available). 
Step 4.  The remaining participants from the current study sample (n = 476 “non-
normal” participants) were processed separately.  In contrast to the methods in Step 1, 
outliers were not removed for this group.  Removal of outliers was previously necessary 
to ensure a normal distribution and that all included participants were cognitively normal, 
as they would serve as the healthy comparison group for constructing norms.  For the 
“non-normal” sample, cognitively healthy performance was not a necessary assumption 
for inclusion; therefore, outliers were not screened out.  Age, education, and polynomial 
terms were recalculated to center values around the mean of the non-normal subjects.  
Then Step 3 was repeated to generate predicted scores and converted into z scores using 
the same coefficients and standard error of the estimate as the normal group.  Normal (n 
= 584) and Non-normal (n = 476) groups datasets were then merged (n = 1060). 
Limitations of RBN approach.  Education history for FHS participants was only 
available in a categorical format (less than 12 years, High School Graduate, Some 
College, College Graduate), thus the RBNs could have been strengthened if continuous 
education history was available. 
Measures of Gray and White Matter Volume 
Those participants with imaging data (n = 823) were seen for MRI on the same 
day as their exam 9 neuropsychological evaluation.  Reasons individuals might not have 
undergone an MRI include refusal due to scheduling, claustrophobia, or personal reasons; 
positive pregnancy test; and medical contraindication such as a recent tattoo, permanent 
24 
 
dentistry, and metallic or electronic implant.  Those who participated in MRI at exam 9 
were significantly younger (Mean Age: participants without MRI = 73.42 years, 
participants with MRI = 70.89) and better educated at Exam 9; however, true between 
group differences for education were very small (Education, No: M = 3.09, Yes: M = 
3.27).  See Figures 1 and 2. 
 
  





Figure 2. Histogram of Education Group by Available MRI Data. 
 
Participants were imaged on a Siemens Magnetom 1 T field strength magnetic 
resonance machine using a T2-weighted double spin-echo coronal imaging sequence of 4 
mm contiguous slices from nasion to occiput with a repetition time (TR) of 2420 ms, 
echo time (TE) of TE1 20/TE2 90 ms; echo train length 8 ms; field of view (FOV) 22 cm 
and an acquisition matrix of 182 × 256 interpolated to a 256 × 256 with one excitation. 
Methods for the measurement of region and overall brain matter volumes from 
structural MRI within the Framingham cohorts have been described in detail elsewhere 
(DeCarli et al., 2005).  Briefly, quantification of regional brain volumes required a multi-
step process. First, removal of the skull and other non-brain tissue from the image.  
Structural MRI brain images are then nonlinearly registered to a minimal deformation 
template synthetic brain image, which provides a reference for computer-directed image 
separation and is adapted for ages 60 and above.  For segmentation of brain from 
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cerebrospinal fluid (CSF), a difference image was created by subtracting the second echo 
image from the first echo image.  Image intensity non-uniformities were then removed 
from the difference image.  Gray and white matter segmentation was accomplished using 
an expectation-maximization algorithm that iteratively refines the segmentation estimates 
to produce outputs that were the most consistent with the input intensities from the 
native-space T1 images, along with a model of image smoothness.  At each iteration, the 
algorithm used a Gaussian model of T1-weighted image intensity for each tissue class in 
order to produce a segmentation.  This methodology yielded values for total gray and 
white matter volumes in cubic centimeters for regions above the tentorium and excluding 
brain matter in the cerebellum and brain stem.  
Differences in head size accounts for some of the interindividual differences on 
MRI variables and measures are typically adjusted to account for this (Mathalon, 
Sullivan, Rawles, & Pfefferbaum, 1993).  To control for the effect of head size, three 
methods were considered: a proportional method, a residualized method, and a 
regression-based method (Barnes et al., 2010; O’Brien et al., 2006; Sanfilipo, Benedict, 
Zivadinov, & Bakshi, 2004).  In the regression-based method, a measure of head size is 
included as a covariate along with any independent variables, such that any associations 
between the region of interest (ROI) and the independent variable take into account any 
baseline variation in head size that may contribute to true score variance.  The 
residualized method is similar to the regression-based method, but only the head size 
measure is used in the regression equation in order to produce a residualized value of the 
ROI after removing the influence of head size.  The residuals of this first regression are 
then used in place of the original variable for any further analyses. 
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In the proportional method, the ROI is expressed as a percentage of a highly 
correlated region indicative of head size in order to normalize the size of the ROI in terms 
of its relative ratio to the designated region.  The head size measure needs to be highly 
correlated in order to reduce the likelihood of introducing unexplained error into the ROI.  
For this study, Total Cranial Volume (TCV) for the region above the tentorium served as 
the measure of head size, consistent with previous FHS studies (Aparicio et al., 2017; 
DeCarli et al., 2005; Seshadri et al., 2004); Gray matter, Pearson r = .877; White matter, 
Pearson r = .865; see Figures 3 and 4).  
 
Formula:   ROI volume% = (ROI/TCV) * 100  (1) 
 
The resulting variables of interest are thus Total Percentage Gray Matter and Total 





Figure 3. Simple Scatterplot of Fit Line of TCV by Total Gray Matter Volume. 
 
 




Several factors for this study contributed to selecting the proportional method.  
First, it had the advantage of being intuitive, and preserved the same units of measure as 
the ROI and head size reference region.  Second, because there was no literature to 
suggest that CV risk may affect head size (Aparicio et al., 2017; Seshadri et al., 2004), 
there was no concern that TCV might also be impacted by the independent variables in 
the study, which would have the effect of obscuring neuroanatomical differences 
attributable to CV risk factors.  Lastly, the regression-based methods were intended for 
situations in which there is a control group or when operating within a question without 
classifications (O’Brien et al., 2006).  This was inconsistent with the methods in the 
present design, because the study had two sets of classifiers and no true control group. 
Analysis Plan 
 The hypotheses for the present study were tested using a two-step approach with a 
hold-out sample.  Other methods, such as k-fold cross-validation, a more computationally 
expensive approach common in machine learning studies, were also considered.  K-fold 
cross-validation approximates the separation of a hold-out group through repeated tests in 
which the data is split into k roughly equal proportions, and one proportion of the total 
sample is held out as a test set during each validation, and incorporated into the training 
set during all other validations, with the process repeated k times.  True hold out samples 
have the benefit of being entirely uninvolved in the initial testing of the analysis, and are 
considered ideal when the data size allows for it (Hastie, Tibshirani, & Friedman, 2009).  
For this approach, approximately two-thirds (n = 729) of the initially identified 
sample (n = 1060) was randomly assigned to the Test analysis, and the remaining third (n 
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= 331) were assigned to the Validation analysis.  This process was repeated for the 
subsample of participants who contributed MRI data (total sub-sample: n = 823; Test: n = 
538; Validation: n = 285).  Selection of sample proportions to dedicate to the Test and 
Validation groups was based on recommendations in Schorfheide & Wolpin (2016).  
Step 1.  For the Test step, in which the analysis followed a Rough CDA plan (Fife 
& Rodgers, 2019), eight linear regressions were performed.  For each regression, one 
neuropsychological test (Digit Symbol, Verbal Fluency, Similarities, BNT, Logical 
Memory, and Visual Reproduction) or MRI variable (Total Percentage Gray Matter and 
Total Percentage White Matter) served as the dependent variable, with treatment history 
for hypertension and treatment history for lipids entered as IVs, along with an interaction 
variable for comorbidity of the IVs (TxHxHypertension*TxHxLipids).  
To assess the comparative value of analyzing the relations of NP variables with 
RBNs, regression of NP measures were performed with raw NP scores as the dependent 
variables and again with RBN NP scores as the dependent variable.  The independent 
variables and interaction variable remained the same across all analyses. The analyses of 
raw score NP variables and MRI variables also included demographics covariates, i.e., 
age, education, and sex at birth, consistent with previous studies (DeCarli et al., 2005).  
The effects of age, education and sex at birth on NP measures were already accounted for 
through the RBN procedures.  In total, 14 regressions were performed using the Test 
subsample (6 raw NP measure score, 6 RBN NP measure score, 2 MRI measures).  
Given that these data were drawn from a community sample of otherwise healthy 
individuals, any impairment observed was expected to be relatively minor and not of 
clinical concern.  As a baseline, effect sizes were considered not meaningful when the 
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partial eta2 value accounted for less than one percent of variance.  In the process of 
refining the analytical model used to assess the Test data set, interaction terms and 
covariates that were not both statically significant (meeting or exceeding an alpha level of 
0.05) and with a meaningful effect size were excluded from the model.  In addition to 
effect sizes, visual inspection of added variable plots guided decisions about meaningful 
findings, consistent with a Rough CDA strategy.  These effect sizes and graphics 
informed the expected association strength to be seen when the analyses were repeated in 
the separate Validation group. 
Step 2.  For the Validation step, the 14 regressions previously described were 
repeated using the Validation hold-out group in order to identify consistently supported 
relations between treatment history variables and NP & MRI outcomes, within a strict 
CDA paradigm.  Meaningful findings were informed by analyses meeting or exceeding 
an alpha level of 0.05 or by yielding an effect size consistent with Step 1 analyses.  
Interpretation of findings.  For each of the six NP outcome measures assessed, 
four regression analyses were planned.  To reduce potential of type 1 errors, individual 
NP measures were only considered to be meaningfully associated with CV risk when all 






Between Group Differences for Demographics 
Tables 4 and 5 summarize group means and standard deviations for age and BMI, 
as well as group frequencies for education and gender distribution, for treatment history 
for hypertension (TxHxHypertension) and treatment history for hyperlipidemia 
(TxHxLipids).  
Age significantly differed among all three groups for TxHxHypertension (all p-
values < .05), with the Inconsistently Treated group presenting with older age than Never 
Treated, and Consistently Treated presenting with older age than Inconsistently Treated.  
This pattern was also observed when considering only participants who contributed MRI 
data (all p-values < .01).  For the TxHxLipids groups, age did not significantly differ 
between the Never Treated and Inconsistently Treated groups (Mean difference = 1.38, 
Std Error = 0.66, p > .05).  All other 2-group comparisons were significantly different (all 
p-values < .001), with greater degree of treatment history presenting with older age.  As 
before, this pattern was also seen when considering only those participants with MRI data 
(Never Treated vs Inconsistently Treated: p > .05; all other p-values < .001). 
BMI among TxHxHypertension groups significantly differed between all groups 
(ps < .05) and among all but one of the TxHxLipids groups (all ps < .05).  Inconsistently 
Treated and Consistently Treated groups for TxHxLipids did not differ (Mean difference 
= 0.43, Std Error = 0.41, p > .05).  For the participants who contributed MRI data, 
Inconsistently Treated and Consistently Treated groups for both TxHxHypertension and 
TxHxLipids did not differ (TxHxHypertension: Mean difference = 0.94, Std Error = 0.51, 
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p > .05; TxHxLipids: Mean difference = 1.52, Std Error = 0.42, p > .05).  All other group 
comparisons were significant (p < .05). 
Considering education, the College Graduate group was the largest education 
group for TxHxHypertension and TxHxLipids for both the full sample and for only the 
participants with MRI data.  The Never Treated group from the full sample for 
TxHxHypertension was the only instance in which the next largest education group was 
not participants with Some College.  For the Never Treated TxHxHypertension group, the 
second largest education group was High School Graduate.  Less than 1 percent of any 
group had fewer than 12 years of education.  Education group representation only 
significantly differed among TxHxHypertension groups for the Never Treated and 
Consistently Treated groups (p < .05).  Among TxHxLipid groups, the education group 
representation differed for the Inconsistently Treated and Consistently Treated groups (p 
< .05).  
With the exception of the MRI sample, more than 50% of all groups were Female 
and the Consistently Treated group accounted for more than half of all participants with 
respect to TxHxHypertension.  For the MRI sample, the Consistently Treated groups for 
TxHxHypertension had a greater representation of Male Sex at Birth compared to lower 
levels of treatment history. 
Test Set 
 Consistent with a Rough CDA approach to data analysis (Fife & Rodgers, 2019; 
Tukey, 1977), the relation between CV treatment group and NP test performance was 
first examined through the analyses of a Test dataset consisting of approximately 69% of 
the original total sample of 1060 participants (Test sample n = 729).  The remaining 
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participants (n = 331) served as a hold-out group used to validate results obtained in the 
Test set.  
To demonstrate the utility of regression-based norms (RBN), both raw score NP 
measures and RBN NP scores were evaluated.  Effect sizes obtained in the Test Set 
analyses informed decisions for refining the model.  In instances where the interaction 
term had a non-significant p-value and a small effect size (i.e.: partial eta2 < 1%), the 
interaction term was dropped from the model and the analysis was repeated.  Levene’s 
Test of Equality of Error Variance indicated that assumptions of homoscedasticity were 
met for all analyses.  This was in agreement with visual inspections of residual plots.  
ANOVA and ANCOVA summary tables for finalized models using NP raw scores, RBN 
scores, and MRI measures from the Test data set are available in Appendix B.  
Naming/ lexical access. Relations between CV risk and Lexical Access were 
examined with the Boston naming Test (BNT) and the Similarities subtest.  
Boston naming test (RBN score).  When considering this relation in the context 
of RBNs for the BNT, the interaction term for TxHxHypertension and TxHxLipids was 
non-significant (p > .05) and evidenced a less-than-meaningful effect size (partial eta2 = 
.009).  Therefore, the decision was made to remove the interaction term from the model 
and re-run the analysis with only the treatment history independent variables. Table 6 
shows the ANOVA table for this analysis, which found no evidence of a meaningful 
relation between TxHxHypertension or TxHxLipids and returned very small effect sizes 
explaining less than 1 percent of variance (TxHxHypertension partial eta2 = .001; 
TxHxLipids partial eta2 = .003).  Visual inspection of added variable plots for 
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TxHxHypertension and TxHxLipids also indicated no meaningful relation between 




RBN Boston Naming Test Model 
 
ANOVA – RBN BNT Model 
Cases  Sum of Squares  df  Mean Square  F  p  η²  η² p  
TxHxHypertension   1.147  2   0.573   0.358   0.699   0.001   0.001   
TxHxLipids   3.209  2   1.605   1.003   0.367   0.003   0.003   
Residuals   1102.344   689   1.600             
Note.  Type III Sum of Squares  
Interaction term excluded 
 
 
Boston naming test (Raw score).  Considering the relation for BNT raw score 
performance and CV risk factors when controlling for demographic variables, the 
interaction term for TxHxHypertension and TxHxLipids was again found to be non-
significant (p > .05) with a similar effect size (partial eta2  = .011).  The interaction effect 
size was large enough to be considered meaningful (partial eta2  > .01), but was not 
supported by a significant p-value, reducing confidence for including the term in the 
model.  Age and education, but not sex at birth, were significantly associated with BNT 
performance.  The interaction term and sex at birth were excluded and the model was re-
analyzed.  Table 7 shows the results of the ANCOVA table for this analysis.  Consistent 
with the RBN BNT analysis, effect sizes of much less than 1 percent were observed for 
TxHxHypertension or TxHxLipids (TxHxHypertension partial eta2 > .001; TxHxLipids 
partial eta2 = .001).  Visual inspection of added variable plots for TxHxHypertension and 
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TxHxLipids did not support a meaningful association between the CV risk variables and 




Raw Score Boston Naming Test Model 
 
ANCOVA – Raw Scores BNT Model 
Cases  Sum of Squares  df  Mean Square  F  p  η²  η² p  
TxHxHypertension   10.312   2   5.156   1.863   0.157   0.009   0.010   
TxHxLipids   2.843   2   1.422   0.514   0.599   0.003   0.003   
Age  42.317   1   42.317   15.292   < .001   0.038   0.041   
Education   56.200   1   56.200   20.310   < .001   0.051   0.054   
Residuals   993.417   359   2.767             
Note.  Type III Sum of Squares  
Interaction term and sex at birth excluded 
 
 
The results of both the RBN and raw score analyses suggested that repeating the 
analysis with the Validation data set would not find a relation between either CV risk 
factor and BNT performance. 
Similarities (RBN score).  The interaction term for TxHxHypertension and 
TxHxLipids was non-significant with a very small effect size (partial eta2 = .006) when 
examining the RBN performance on the Similarities subtest.  This informed the decision 
to remove the interaction term from the model and re-run the analysis with only the 
treatment history independent variables. Table 8 shows the resulting ANOVA table for 
this analysis, which found a small but meaningful relation between TxHxHypertension 
and this measure of verbal reasoning (partial eta2 = .016).  In particular, a small between-
group effect size was found between the highest and lowest levels of TxHxHypertension 
(Cohen’s d = .29).  TxHxLipids was not significantly associated with Similarities 
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performance (partial eta2 = .001).  Meeting expectations for the small effect size 
observed, visual inspection of the added variable plots for TxHxHypertension and 
TxHxLipids showed only minor differences between groups. 
 
Table 8  
 
RBN Similarities Model 
 
ANOVA – RBN Similarities Model 
Cases  Sum of Squares  df  Mean Square  F  p  η²  η² p  
TxHxHypertension   15.430  2   7.715   5.958   0.003   0.016   0.016   
TxHxLipids   0.948  2   0.474   0.366   0.694   0.001   0.001   
Residuals   925.847   715   1.295             
Note.  Type III Sum of Squares  
Interaction term excluded 
 
 
Similarities (raw score).  In analysis of Similarities raw score performance and 
CV risk factors when controlling for demographic variables, the interaction term for 
TxHxHypertension and TxHxLipids was again found to be non-significant (p > .05) with 
a small effect size (partial eta2 = .005).  Age and education, but not sex at birth, were 
significantly associated with Similarities performance.  The interaction term and sex at 
birth were excluded and the model was re-analyzed.  Table 9 shows the results of 
ANCOVA table for this analysis.  Compared with the RBN Similarities analysis, 
TxHxHypertension demonstrated a significant (p < .05) but smaller than meaningful 
association with raw score Similarities performance when covarying for age and 
education (partial eta2 = .009). TxHxLipids was not significantly associated with 
Similarities performance (partial eta2 < .001).  Visual inspection of added variable plots 
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for TxHxHypertension and TxHxLipids was consistent with the results of the RBN 
Similarities analysis. 
 
Table 9  
 
Raw Score Similarities Model 
 
ANCOVA – Raw Score Similarities Model 
Cases  
Sum of 
Squares  df  
Mean 
Square  F  p  η²  η² p  
TxHxHypertension   67.162   2   33.581   3.281   0.038   0.007   0.009   
TxHxLipids   2.004   2   1.002   0.098   0.907   < .001  < .001  
Age   117.570   1   117.570   11.489   < .001   0.013   0.016   
Education   1832.576   1   1832.576   179.075   < .001   0.196   0.200   
Residuals   7317.008   715   10.234              
Note.  Type III Sum of Squares  
Interaction term and sex at birth excluded 
 
 
The results of both the RBN and raw score analyses suggested that repeating the 
analysis with the Validation data set would show a relation between TxHxHypertension 
and Similarities performance. 
Processing speed.  Relations between CV risk and Processing Speed were 
examined with the Digit Symbol Coding subtest and the Verbal Fluency test.  
Digit symbol coding (RBN score).  For the relation between RBN performance on 
Digit Symbol Coding and CV risk factors, the interaction term for TxHxHypertension 
and TxHxLipids was non-significant (p > .05) with a very small effect size (partial eta2 = 
.002).  The decision was made to remove the interaction term from the model and re-run 
the analysis with only the treatment history independent variables.  Table 10 shows the 
ANOVA table for this analysis, which found a meaningful relation between 
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TxHxHypertension and this task of graphomotor function and processing speed (partial 
eta2 = .014).  A small between-group effect size was found between the highest and 
lowest levels of TxHxHypertension (Cohen’s d = .26).  TxHxLipids returned a small 
effect size explaining less than 1 percent of variance (partial eta2 = .002).  Visual 
inspection of added variable plots for TxHxHypertension and TxHxLipids was consistent 




RBN Digit Symbol Coding Model 
 
ANOVA – RBN Digit Symbol Coding Model  
Cases  Sum of Squares  df  Mean Square  F  p  η²  η² p  
TxHxHypertension   9.669   2   4.835   4.683   0.010   0.014   0.014   
TxHxLipids   1.356   2   0.678   0.657   0.519   0.002   0.002   
Residuals   665.871   645   1.032             
Note.  Type III Sum of Squares  
Interaction term excluded 
 
 
Digit symbol coding (raw score).  For raw score Digit Symbol Coding, the effect 
size for the interaction term for TxHxHypertension and TxHxLipids was large enough to 
be considered meaningful (partial eta2  = .011), but was not supported by a significant p-
value (p > .05), reducing confidence for including the term in the model. Age, education 
and sex at birth were significantly associated with Digit Symbol Coding performance.  
The interaction term was excluded and the model was re-analyzed.  Table 11 shows the 
results of the ANCOVA table for this analysis.  Consistent with the RBN Digit Symbol 
Coding analysis, TxHxHypertension demonstrated a small but meaningful association 
with raw score Digit Symbol Coding performance when controlling for age, education, 
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and sex at birth (TxHxHypertension: partial eta2 = .015; TxHxLipids: partial eta2 = .002).  
Visual inspection of added variable plots for TxHxHypertension and TxHxLipids agreed 





Raw Score Digit Symbol Coding Model 
 
ANCOVA – Raw Score Digit Symbol Coding Model 
Cases  Sum of Squares  df  Mean Square  F  p  η²  η² p  
TxHxHypertension   1219.650   2   609.825   4.797   0.009   0.012   0.015   
TxHxLipids   191.115   2   95.558   0.752   0.472   0.002   0.002   
Age   14354.168   1   14354.168   112.901   < .001   0.136   0.150   
Education   3513.599   1   3513.599   27.636   < .001   0.033   0.041   
Sex at Birth   4425.942   1   4425.942   34.812   < .001   0.042   0.051   
Residuals   81623.590   642   127.140             
Note.  Type III Sum of Squares  
Interaction term excluded 
 
 
The results of both the RBN and raw score analyses suggested that repeating the 
analysis with the Validation data set would show a relation between TxHxHypertension 
and Digit Symbol Coding performance. 
Verbal fluency (RBN score).  The interaction term for TxHxHypertension and 
TxHxLipids was non-significantly associated with RBN Verbal Fluency performance (p 
> .05) and evidenced a smaller than meaningful effect size (partial eta2 = .008).  
Therefore, the decision was made to remove the interaction term from the model and re-
run the analysis with only the treatment history independent variables. Table 12 shows 
the ANOVA table for this analysis, which found evidence of a meaningful relation with 
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TxHxHypertension, but not TxHxLipids (TxHxHypertension partial eta2 = .016; 
TxHxLipids partial eta2 = .005). Visual inspection of added variable plots for 
TxHxHypertension and TxHxLipids also indicated lower performance on RBN Verbal 
Fluency among the Consistently Treated group for TxHxHypertension compared to other 





RBN Verbal Fluency Model 
 
ANOVA – RBN Verbal Fluency Model 
Cases  Sum of Squares  df  Mean Square  F  p  η²  η² p  
TxHxHypertension   0.842   2   0.421   5.637   0.004   0.016   0.016   
TxHxLipids   0.281   2   0.141   1.884   0.153   0.005   0.005   
Residuals   51.876   695   0.075             
Note.  Type III Sum of Squares  
Interaction term excluded 
 
 
Verbal fluency (raw score).  For raw score performance on the Verbal Fluency 
task, the interaction term for TxHxHypertension and TxHxLipids was not significant (p > 
.05) with a similar effect size (partial eta2 = .008).  Age and education, but not sex at 
birth, were significantly associated with BNT performance.  The interaction term and sex 
at birth were excluded and the model was re-analyzed. Table 13 shows the ANCOVA 
table for this analysis.  In contrast to the RBN analysis, no meaningful relation with 
TxHxHypertension or TxHxLipids was observed (TxHxHypertension: partial eta2 = .007; 
TxHxLipids: partial eta2 = .002).  Visual inspection of added variable plots for 
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TxHxHypertension and TxHxLipids also indicates no meaningful relation between 




Raw Score Verbal Fluency Model 
 
ANCOVA – Raw Score Verbal Fluency Model  
Cases  Sum of Squares  df  Mean Square  F  p  η²  η² p  
TxHxHypertension   667.126   2   333.563   2.409   0.091   0.006   0.007   
TxHxLipids   196.718   2   98.359   0.710   0.492   0.002   0.002   
Age   2503.217   1   2503.217   18.078   < .001   0.023   0.025   
Education   7119.014   1   7119.014   51.411   < .001   0.067   0.069   
Residuals   96099.105   694   138.471             
Note.  Type III Sum of Squares  
Interaction term and sex at birth excluded 
 
 
The results of the RBN and raw score analyses did not align and suggested that 
repeating the analysis with the Validation data set would find a relation between 
TxHxHypetension and verbal fluency performance, but only in the context of RBNs. 
Episodic memory.  Relations between CV risk and Episodic Memory were 
examined with the Logical Memory subtest and the Visual Reproduction subtest.  
Logical memory (RBN score).  For the relation between RBN performance on 
Logical Memory delayed free recall and CV risk factors, the interaction term for 
TxHxHypertension and TxHxLipids was non-significant (p > .05) with a very small 
effect size (partial eta2 = .004).  The decision was made to remove the interaction term 
from the model and re-run the analysis with only the treatment history independent 
variables.  Table 14 shows the ANOVA table for this analysis, which found no evidence 
of a meaningful relation between TxHxHypertension or TxHxLipids and returned very 
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small effect sizes explaining less than 1 percent of variance (TxHxHypertension partial 
eta2 = .004; TxHxLipids partial eta2 = .002).  Visual inspection of added variable plots for 
TxHxHypertension and TxHxLipids also indicated no meaningful relation between 




RNB Logical Memory Delayed Free Recall Model 
 
ANOVA – RNB Logical Memory Delayed Free Recall Model  
Cases  
Sum of 
Squares  df  
Mean 
Square  F  p  η²  η² p  
TxHxHypertension   2.782   2   1.391   1.366   0.256   0.004   0.004   
TxHxLipids   1.319   2   0.659   0.648   0.523   0.002   0.002   
Residuals   719.632   707   1.018             
Note.  Type III Sum of Squares  
Interaction term excluded 
 
 
Logical memory (raw score).  For raw score Logical Memory delayed free recall, 
the interaction term for TxHxHypertension and TxHxLipids was again found to be non-
significant (p > .05) with a similar effect size (partial eta2 = .005).  Age, education, and 
sex at birth were significantly associated with verbal episodic memory performance on 
this task.  The interaction term was excluded and the model was re-analyzed. Table 15 
shows the results of the ANCOVA table for this analysis.  Consistent with the RBN 
analysis, no evidence of a meaningful relation between TxHxHypertension or 
TxHxLipids was found when controlling for age, education and sex (TxHxHypertension: 
partial eta2 = .006; TxHxLipids: partial eta2 < .001).  Visual inspection of added variable 






Raw Score Logical Memory Delayed Free Recall Model 
 
ANCOVA – Raw Score Logical Memory Delayed Free Recall Model  
Cases  Sum of Squares  df  Mean Square  F  p  η²  η² p  
TxHxHypertension   51.066   2   25.533   1.993   0.137   0.005   0.006   
TxHxLipids   13.226   2   6.613   0.516   0.597   0.001   0.001   
Age   269.078   1   269.078   20.999   < .001   0.027   0.029   
Education   549.517   1   549.517   42.884   < .001   0.055   0.057   
Sex at Birth   166.099   1   166.099   12.962   < .001   0.016   0.018   
Residuals   9021.086   704   12.814             
Note.  Type III Sum of Squares  
Interaction term excluded 
 
 
The results of both the RBN and raw score analyses suggested that repeating the 
analysis with the Validation data set would not find a relation between either CV risk 
factor and Logical Memory performance. 
Visual reproduction (RBN score).  The interaction term for TxHxHypertension 
and TxHxLipids was non-significantly associated with RBN Visual Reproduction 
delayed free recall performance (p > .05) and evidenced a less-than-meaningful small 
effect size (partial eta2 = .009).  Therefore, the decision was made to remove the 
interaction term from the model and re-run the analysis with only the treatment history 
independent variables.  Table 16 shows the ANOVA table for this analysis, which found 
no evidence of a meaningful relation between TxHxHypertension or TxHxLipids and 
returned very small effect sizes explaining less than 1 percent of variance 
(TxHxHypertension partial eta2 = .006; TxHxLipids partial eta2 = .003).  Visual 
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inspection of added variable plots for TxHxHypertension and TxHxLipids also indicates 




RBN Visual Reproduction Delayed Free Recall Model 
 
ANOVA – RBN Visual Reproduction Delayed Free Recall Model  
Cases  Sum of Squares  df  Mean Square  F  p  η²  η² p  
TxHxHypertension   4.671   2   2.335   2.206   0.111   0.006   0.006   
TxHxLipids   2.252   2   1.126   1.064   0.346   0.003   0.003   
Residuals   754.869   713   1.059             
Note.  Type III Sum of Squares  
Interaction term excluded 
 
 
Visual reproduction (raw score). For raw score performance on the Visual 
Reproduction delayed free recall task, the interaction term for TxHxHypertension and 
TxHxLipids was not significant (p > .05) with an effect size (partial eta2 = .010) similar 
to the RBN analysis.  Age and education, but not sex at birth, were significantly 
associated with visual episodic memory performance.  The interaction term and sex at 
birth were excluded and the model was re-analyzed. Table 17 shows the ANCOVA table 
for this analysis.  Consistent with the RBN analysis, no meaningful relation with 
TxHxHypertension or TxHxLipids was observed (TxHxHypertension: partial eta2 = .007; 
TxHxLipids: partial eta2 = .003).  Visual inspection of added variable plots for 
TxHxHypertension and TxHxLipids also indicated no meaningful relation between 







Raw Score Visual Reproduction Delayed Free Recall Model 
 
ANCOVA – Raw Score Visual Reproduction Delayed Free Recall Model  
Cases  Sum of Squares  df  Mean Square  F  p  η²  η² p  
TxHxHypertension   36.130   2   18.065   2.511   0.082   0.006   0.007   
TxHxLipids   13.533   2   6.767   0.941   0.391   0.002   0.003   
Age   549.893   1   549.893   76.441   < .001   0.092   0.097   
Education   252.441   1   252.441   35.092   < .001   0.042   0.047   
Residuals   5114.680   711   7.194             
Note.  Type III Sum of Squares  
Interaction term and Sex at Birth excluded 
 
 
The results of both the RBN and raw score analyses suggested that repeating the 
analysis with the Validation data set would not find a relation between either CV risk 
factor and Visual Reproduction performance. 
Volumetric measures of whole brain gray and white matter.  Relations 
between CV risk and brain matter volumes were examined to determine if group-based 
differences in gray and white matter volume corresponded with observed 
neuropsychological performance.  
Gray matter volume.  The proportional measure of total brain gray matter volume 
after correcting for head size was initially entered into a model with TxHxHypertension, 
TxHxLipids, and the interaction term of these two independent variables, and with age, 
education and sex at birth as covariates.  In this first model, the interaction term for 
TxHxHypertension and TxHxLipids was non-significant (p > .05) with a very small 
effect size (partial eta2 = .006).  Age and sex at birth, but not education, were 
significantly associated with gray matter volume.  The decision was made to remove the 
interaction term and education from the model and re-run the analysis.  Table 18 shows 
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the ANCOVA table for this analysis, which found no evidence of a meaningful relation 
between TxHxHypertension or TxHxLipids and returned very small effect sizes 
explaining less than 1 percent of variance (TxHxHypertension partial eta2 = .004; 
TxHxLipids partial eta2 = .004).  Visual inspection of added variable plots for 
TxHxHypertension and TxHxLipids also indicated no meaningful relation between 




Total Percentage Gray Matter Volume Model 
 
ANCOVA – Total Percentage Gray Matter Volume Model 
Cases  Sum of Squares  df  Mean Square  F  p  η²  η² p  
TxHxHypertension   5.696   2   2.848   1.158   0.315   0.003   0.004   
TxHxLipids   4.663   2   2.331   0.948   0.388   0.003   0.004   
Age   343.040   1   343.040   139.504   < .001   0.192   0.208   
Sex at Birth   131.263   1   131.263   53.381   < .001   0.073   0.091   
Residuals   1305.730   531   2.459             
Note.  Type III Sum of Squares  
Interaction term and Education excluded 
 
 
White matter volume.  Consistent with the model for Gray Matter, the 
proportional measure of total brain white matter volume after correcting for head size 
was initially entered into a model with TxHxHypertension, TxHxLipids, and the 
interaction term of these two independent variables, and with age, education and sex at 
birth as covariates.  As with the gray matter model, the interaction term for 
TxHxHypertension and TxHxLipids was found to be non-significant (p > .05).  Notably, 
the effect size was larger than in the gray matter model (partial eta2 = .014), but remained 
small in comparison to other terms in the model.  Age and sex at birth, but not education, 
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were significantly associated with the model. The interaction term and education were 
excluded and the model was re-analyzed. Table 19 shows the results of the ANCOVA 
table for this analysis.  Consistent with the gray matter analysis, no evidence of a 
meaningful relation with TxHxHypertension or TxHxLipids was found when controlling 
for age and education (TxHxHypertension: partial eta2 = .002; TxHxLipids: partial eta2 < 
.001).  Visual inspection of added variable plots for TxHxHypertension and TxHxLipids 




Total Percentage White Matter Volume Model 
 
ANCOVA – Total Percentage White Matter Volume Model  
Cases  Sum of Squares  df  Mean Square  F  p  η²  η² p  
TxHxHypertension   3.273   2   1.637   0.403   0.668   0.001   0.002   
TxHxLipids   1.052   2   0.526   0.130   0.878   < .001   < .001  
Age   381.432   1   381.432   93.958   < .001   0.148   0.150   
Sex at Birth   41.956   1   41.956   10.335   0.001   0.016   0.019   
Residuals   2155.645   531   4.060              
Note.  Type III Sum of Squares  
Interaction term and Education excluded 
 
 
The results of these analyses suggested that repeating the analysis with the 
Validation data set would not find a relation between either CV risk factor and 
proportional measures of total gray and white matter volume. 
Test set summary. Table 6 summarizes the results of Test set analyses.  No final 
model for any of the analyses included an interaction term for TxHxHypertension and 
TxHxLipids. TxHxHypertension was associated with performance on RBN Verbal 
49 
 
Fluency, raw score Digit Symbol Coding, RBN Digit Symbol Coding, raw score 
Similarities and RBN Similarities; however effect sizes remained small across all 
analyses, with partial eta2 values falling between .010 and .020.  
Verbal Fluency task performance was the only Test set measure to show 
inconsistent findings between raw score and RBN analyses.  Any measure of verbal 
production is highly related to demographic covariates, in particular education for letter 
fluency tasks.  Thus, this may be related to the exclusion of the covariate sex at birth 
when refining the raw score model, as sex at birth was a covariate included in the 
creation of the RBN performance scores.  The RBN Verbal Fluency analysis reports an 
effect size of TxHxHypertension more than twice the size of the non-significant raw 
score partial eta2 (RBN partial eta2 = .016; Raw partial eta2 = .007).  The effect size of 
sex at birth in the initial model was small (partial eta2 = .004), so the decision to exclude 
remains supported.  
Among raw score covariates, age and education were consistently associated with 
raw score neuropsychological performance, although sex at birth was inconsistently 
included in final models and was associated with Digit Symbol Coding and Logical 
Memory delayed free recall only.  Age and sex at birth, but not education, were 
associated with MRI measures. 
 
Validation Set 
 Following analysis with the Test data in which the final model for each analysis 
was determined, ANOVA and ANCOVA analyses using the final models were repeated 
using the Validation data set, a hold-out sample of one-third of the original study sample 
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whose data had not been used in the earlier analyses.  Analysis with this group represents 
a replication of the Test data set results in an independent sample of 331 participants 
randomly withheld from the Test set analyses.  
As with the Test set, both raw score NP measures and RBN NP scores were 
evaluated for evidence of significant relations between CV risk factors and NP 
performance.  Final models and effect sizes obtained through evaluation of the Test data 
set informed expectations for analyses in the Validation sample.  ANOVA and ANCOVA 
summary tables for finalized models using NP raw scores, RBN scores, and MRI 
measures from the Test data set are available in Appendix D.  
Naming/ lexical access.  Relations between CV risk and Lexical Access were 
examined with the Boston naming Test (BNT) and the Similarities subtest.  
Boston naming test (RBN score).  Table 20 shows the ANOVA table for this 
analysis.  Consistent with the Test set analysis, no evidence of a meaningful relation was 
observed between RBN BNT performance and TxHxHypertension or TxHxLipids (p > 
.05). Both independent variables produced noticeably larger effect sizes compared to the 
Test set analysis, indicating poor consistency of findings upon replication 
(TxHxHypertension partial eta2 = .009; TxHxLipids partial eta2 = .012).  This supports 
the conclusion that RBN BNT is not meaningfully associated with CV risk factors.  
Visual inspection of added variable plots for TxHxHypertension and TxHxLipids also 






Table 20  
RBN Boston Naming Test Model 
ANOVA – RBN BNT Model 
Cases  Sum of Squares  df  
Mean 
Square  F  p  η²  η² p  
TxHxHypertension   3.730   2   1.865   1.375   0.254   0.009   0.009   
TxHxLipids   5.132   2   2.566   1.892   0.152   0.012   0.012   
Residuals   425.776   314   1.356             
 
Note.  Type III Sum of Squares  
 
 
Boston naming test (raw score).  As with the other analyses of BNT, the relation 
for BNT raw score performance and CV risk factors when controlling for demographic 
variables was not meaningful. Table 21 shows the results of the ANCOVA table for this 
analysis.  Effect sizes of less than 1 percent were observed for TxHxHypertension and 
TxHxLipids (TxHxHypertension partial eta2 = .003; TxHxLipids partial eta2 = .001).  
Visual inspection of added variable plots for TxHxHypertension and TxHxLipids did not 
support a meaningful relation between the CV risk variables and BNT performance.  
 
Table 21  
 
Raw Score Boston Naming Test Model 
 
ANCOVA – Raw Score BNT Model 
Cases  Sum of Squares  df  Mean Square  F  p  η²  η² p  
TxHxHypertension   3.964   2   1.982   0.414   0.661   0.002   0.003   
TxHxLipids   2.048   2   1.024   0.214   0.808   0.001   0.001   
Age   142.268   1   142.268   29.702   < .001   0.079   0.086   
Education   145.533   1   145.533   30.383   < .001   0.081   0.088   
Residuals   1508.816   315   4.790             




Considering the four analyses of BNT performance across the Test and Validation 
sets, the results of both the RBN and raw score analyses indicate that a meaningful 
relation was not observed between either CV risk factor and BNT performance. 
Similarities (RBN score).  Table 22 shows the resulting ANOVA table for this 
analysis, which replicated the finding of a meaningful relation between 
TxHxHypertension and this measure of verbal reasoning (partial eta2 = .031).  The effect 
size for this relation was twice as large as what was observed in the Test set analysis, 
indicating that there remains some uncertainty as to the degree of impact of CV risk 
factors on verbal reasoning.  As in the Test analysis, a moderate between-group effect 
size was found between the highest and lowest levels of TxHxHypertension (Cohen’s d = 
.41) and TxHxLipids was not significantly associated with Similarities performance 
(partial eta2 = .001).  Visual inspection of the added variable plots for TxHxHypertension 




RBN Similarities Model 
 
ANOVA – RBN Similarities Model 
Cases  Sum of 
Squares  
df  Mean 
Square  
F  p  η²  η² p  
TxHxHypertension   12.970   2   6.485   5.225   0.006   0.031   0.031  
TxHxLipids   0.452   2   0.226   0.182   0.834   0.001   0.001  
Residuals   400.920   323   1.241             
Note.  Type III Sum of Squares  
 
 
Similarities (raw score). Table 23 shows the ANCOVA table for this analysis.  
Consistent with the RBN Similarities analysis, TxHxHypertension, but not TxHxLipids, 
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demonstrated meaningful association with raw score Similarities performance when 
covarying for age and education (TxHxHypertension: partial eta2 = .031; TxHxLipids: 
partial eta2 < .003).  A moderate between-group effect size was found between the 
highest and lowest levels of TxHxHypertension (Cohen’s d = .43).  Visual inspection of 
added variable plots for TxHxHypertension and TxHxLipids was consistent with the 




Raw Score Similarities Model 
 
ANCOVA – Raw Score Similarities Model 
Cases  Sum of Squares  df  Mean Square  F  p  η²  η² p  
TxHxHypertension   92.726   2   46.363   5.076   0.007   0.025   0.031   
TxHxLipids   9.263   2   4.632   0.507   0.603   0.002   0.003   
Age   91.906   1   91.906   10.062   0.002   0.025   0.030   
Education   611.270   1   611.270   66.923   < .001   0.164   0.173   
Residuals   2931.994   321   9.134             
Note.  Type III Sum of Squares  
 
 
The four analyses of Similarities performance across the Test and Validation sets 
indicate that a meaningful relation exists between TxHxHypertension and Similarities 
performance, with greater treatment history relating to poorer measure performance. 
Processing speed.  Relations between CV risk and Processing Speed were 
examined with the Digit Symbol Coding subtest and the Verbal Fluency test.  
Digit symbol coding (RBN score).  For the relation between RBN performance on 
Digit Symbol Coding and CV risk factors, Table 24 shows the ANOVA table for this 
analysis, which found a meaningful relation between TxHxHypertension and this task of 
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graphomotor function and processing speed (partial eta2 = .042).  A moderate between-
group effect size was found between the highest and lowest levels of TxHxHypertension 
(Cohen’s d = .48).  TxHxLipids returned a small effect size explaining less than 1 percent 
of variance (partial eta2 = .004).  These findings support the results of the Test set 
analysis of RBN Digit Symbol Coding, and visual inspection of added variable plots for 




RBN Digit Symbol Coding Model 
 
ANOVA – RBN Digit Symbol Coding Model  
Cases  Sum of Squares  df  Mean Square  F  p  η²  η² p  
TxHxHypertension   14.203   2   7.102   6.564   0.002   0.042   0.042   
TxHxLipids   1.226   2   0.613   0.566   0.568   0.004   0.004   
Residuals   321.320   297   1.082             
Note.  Type III Sum of Squares  
 
 
Digit symbol coding (Raw score).  Table 25 shows the results of the ANCOVA 
table for raw score Digit Symbol Coding.  Consistent with the RBN Digit Symbol Coding 
analysis, TxHxHypertension demonstrated a meaningful association with raw score Digit 
Symbol Coding performance when controlling for age, education and sex at birth 
(TxHxHypertension: partial eta2 = .042; TxHxLipids: partial eta2 < .007).  A large 
between-group effect size was found between the highest and lowest levels of 
TxHxHypertension (Cohen’s d = .63).  Visual inspection of added variable plots for 
TxHxHypertension and TxHxLipids agreed with these findings, showing noticeably 






Raw Score Digit Symbol Coding Model 
 
ANCOVA – Raw Score Digit Symbol Coding Model  
Cases  Sum of Squares  df  Mean Square  F  p  η²  η² p  
TxHxHypertension   1676.518   2   838.259   6.490   0.002   0.032   0.042   
TxHxLipids   285.888   2   142.944   1.107   0.332   0.005   0.007   
Age   3913.683   1   3913.683   30.299   < .001   0.075   0.093   
Education   5597.953   1   5597.953   43.338   < .001   0.107   0.128   
Sex at Birth   2645.028   1   2645.028   20.477   < .001   0.051   0.065   
Residuals   37975.769   294   129.169             
Note.  Type III Sum of Squares  
 
 
Across the four analyses of Digit Symbol Coding performance for the Test and 
Validation sets, a consistent meaningful relation existed between TxHxHypertension and 
both raw score and RBN performance. 
Verbal fluency (RBN score).  Table 26 shows the ANOVA table for this analysis, 
which found evidence of a meaningful relation for RBN Verbal Fluency with 
TxHxHypertension, but not with TxHxLipids (TxHxHypertension partial eta2 = .031; 
TxHxLipids partial eta2 = .004).  A moderate between-group effect size was found 
between the highest and lowest levels of TxHxHypertension (Cohen’s d = .41).  Visual 
inspection of added variable plots for TxHxHypertension and TxHxLipids indicated 
lower performance on RBN Verbal Fluency among the Consistently Treated group for 
TxHxHypertension compared to other groups.  No meaningful relation with TxHxLpids 







RBN Verbal Fluency Model 
 
ANOVA – RBN Verbal Fluency Model  
Cases  Sum of Squares  df  Mean Square  F  p  η²  η² p  
TxHxHypertension   0.801   2   0.401   5.008   0.007   0.031   0.031   
TxHxLipids   0.094   2   0.047   0.589   0.556   0.004   0.004   
Residuals   25.126   314   0.080             
Note.  Type III Sum of Squares  
 
 
Verbal fluency (raw score).  In contrast to the analysis conducted for raw score 
Verbal Fluency in the Test set, the validation analysis for raw scores concurred with the 
RBN analysis and showed a meaningful relation between the NP measure and 
TxHxHypertension, and no relation with TxHxLipids (TxHxHypertension: partial eta2 = 
.020; TxHxLipids: partial eta2 = .002). Table 27 shows the ANCOVA table for this 
analysis.  A moderate between-group effect size was found between the highest and 
lowest levels of TxHxHypertension (Cohen’s d = .34).  Visual inspection of added 




Raw Score Verbal Fluency Model 
 
ANCOVA – Raw Score Verbal Fluency Model  
Cases  Sum of Squares  df  Mean Square  F  p  η²  η² p  
TxHxHypertension   890.845   2   445.423   3.180   0.043   0.018   0.020   
TxHxLipids   96.593   2   48.296   0.345   0.709   0.002   0.002   
Age   633.808   1   633.808   4.525   0.034   0.013   0.014   
Education   4575.913   1   4575.913   32.669   < .001   0.092   0.095   
Residuals   43701.509   312   140.069             





Between the Test set and Validation set analyses, RBN Verbal Fluency 
consistently demonstrated a meaningful association with TxHxHypertension, showing 
poorer performance at higher levels of treatment history.  The replication of the raw score 
analysis with the validation set showed agreement between RBN and raw score measures, 
but failed to replicate the findings of the Test set raw score analysis, which, in contrast, 
found no relation between the NP measure and CV risk factors.  The existence of this 
relation appears likely, but would require further replication with additional datasets to 
verify the degree of impact that CV risk may impart to assessments of Verbal Fluency. 
Episodic memory.  Relations between CV risk and Episodic Memory were 
examined with the Logical Memory subtest and the Visual Reproduction subtest.  
Logical memory (RBN score).  For the relation between RBN performance on 
Logical Memory delayed free recall and CV risk factors, no evidence of a meaningful 
relation with TxHxHypertension or TxHxLipids was observed (TxHxHypertension 
partial eta2 = .003; TxHxLipids partial eta2 < .001). Table 28 shows the ANOVA table for 
this analysis.  Visual inspection of added variable plots for TxHxHypertension and 











RNB Logical Memory Delayed Free Recall Model 
 
ANOVA – RNB Logical Memory Delayed Free Recall Model  
Cases  Sum of Squares  df  Mean Square  F  p  η²  η² p  
TxHxHypertension   1.001   2   0.500   0.511   0.600   0.003   0.003   
TxHxLipids   0.151   2   0.076   0.077   0.926   < .001   < .001  
Residuals   313.219   320   0.979             
Note.  Type III Sum of Squares  
 
 
Logical memory (raw score).  For raw score Logical Memory delayed free recall, 
Table 29 shows the results of the ANCOVA table for this analysis.  Consistent with the 
RBN analysis, no evidence of a meaningful relation between TxHxHypertension or 
TxHxLipids was found when controlling for age, education, and sex at birth 
(TxHxHypertension: partial eta2 < .001; TxHxLipids: partial eta2 < .001).  Visual 





Raw Score Logical Memory Delayed Free Recall Model 
 
ANCOVA – Raw Score Logical Memory Delayed Free Recall Model  
Cases  Sum of Squares  df  Mean Square  F  p  η²  η² p  
TxHxHypertension   2.428   2   1.214   0.098   0.906   < .001  < .001  
TxHxLipids   0.071   2   0.036   0.003   0.997   < .001   < .001  
Age   222.862   1   222.862   18.074   < .001   0.049   0.054   
Education   341.642   1   341.642   27.708   < .001   0.075   0.080   
Sex at Birth   72.145   1   72.145   5.851   0.016   0.016   0.018   
Residuals   3908.673   317   12.330              





The four analyses of Logical Memory performance across the Test and Validation 
sets indicated that no meaningful relation exists between TxHxHypertension or 
TxHxLipids and Logical Memory performance. 
Visual reproduction (RBN score).  Table 30 shows the ANOVA table for this 
analysis, which found no evidence of a meaningful relation between TxHxHypertension 
or TxHxLipids and, consistent with the Test set analysis, returned very small effect sizes 
explaining less than 1 percent of variance (TxHxHypertension partial eta2 = .003; 
TxHxLipids partial eta2 = .006).  Visual inspection of added variable plots for 
TxHxHypertension and TxHxLipids also indicated no meaningful relation between 




RBN Visual Reproduction Delayed Free Recall Model 
 
ANOVA – RBN Visual Reproduction Delayed Free Recall Model  
Cases  Sum of Squares  df  Mean Square  F  p  η²  η² p  
TxHxHypertension   0.954   2   0.477   0.452   0.637   0.003   0.003   
TxHxLipids   2.160   2   1.080   1.022   0.361   0.006   0.006   
Residuals   338.021   320   1.056             
Note.  Type III Sum of Squares  
 
 
Visual reproduction (raw score).  Table 31 shows the ANCOVA table for raw 
score performance on the Visual Reproduction delayed free recall task this analysis.  
Consistent with other analyses, no meaningful relation with TxHxHypertension or 
TxHxLipids was observed (TxHxHypertension: partial eta2 = .002; TxHxLipids: partial 
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eta2 = .008).  Visual inspection of added variable plots for TxHxHypertension and 
TxHxLipids indicated no meaningful relation between independent variables and 




Raw Score Visual Reproduction Delayed Free Recall Model 
 
ANCOVA – Raw Score Visual Reproduction Delayed Free Recall Model  
Cases  Sum of Squares  df  Mean Square  F  p  η²  η² p  
TxHxHypertension   4.806   2   2.403   0.337   0.714   0.002   0.002   
TxHxLipids   17.196   2   8.598   1.205   0.301   0.006   0.008   
Age   282.130   1   282.130   39.532   < .001   0.100   0.111   
Education   234.479   1   234.479   32.855   < .001   0.084   0.094   
Residuals   2269.510   318   7.137             
Note.  Type III Sum of Squares  
 
 
Considering the four analyses of Visual Reproduction performance across the 
Test and Validation sets, the results of both the RBN and raw score analyses indicated 
that a meaningful relation was not observed for Visual Reproduction performance and 
either CV risk factor. 
Volumetric measures of whole brain gray and white matter.  Relations 
between CV risk and brain matter volumes were examined to determine if group-based 
differences in gray and white matter volume corresponded with observed 
neuropsychological performance.  
Gray matter volume.  Table 32 shows the ANCOVA table for this analysis for the 
proportional measure of total brain gray matter volume after correcting for head size.  As 
with the Test set, there was no evidence of a significant association between 
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TxHxHypertension or TxHxLipids and the analysis returned relatively small effect sizes 
when compared to covariates (TxHxHypertension partial eta2 = .013; TxHxLipids partial 
eta2 = .001).  Visual inspection of added variable plots for TxHxHypertension and 
TxHxLipids also indicates no meaningful relation between independent variables and 




Total Percentage Gray Matter Volume Model 
 
ANCOVA – Total Percentage Gray Matter Volume Model  
Cases  Sum of Squares  df  Mean Square  F  p  η²  η² p  
TxHxHypertension   10.525   2   5.262   1.818   0.164   0.010   0.013   
TxHxLipids   1.075   2   0.537   0.186   0.831   < .001   0.001   
Age   185.736   1   185.736   64.182   < .001   0.170   0.188   
Sex at Birth   88.790   1   88.790   30.682   < .001   0.081   0.099   
Residuals   804.502   278   2.894             
Note.  Type III Sum of Squares  
 
 
White matter volume.  As with the gray matter model, Table 33 shows the results 
of the ANCOVA table for the analysis of CV risk factors, age, sex at birth, and the 
proportional measure of total brain white matter volume.  This analysis found no 
evidence of a significant association with TxHxHypertension or TxHxLipids when 
controlling for age and sex at birth (TxHxHypertension: partial eta2 = .013; TxHxLipids: 
partial eta2 = .006).  Visual inspection of added variable plots for TxHxHypertension and 








Total Percentage White Matter Volume Model 
 
ANCOVA – Total Percentage White Matter Volume Model  
Cases  Sum of Squares  df  Mean Square  F  p  η²  η² p  
TxHxHypertension   17.159   2   8.579   1.845   0.160   0.011   0.013   
TxHxLipids   7.675   2   3.838   0.825   0.439   0.005   0.006   
Age   236.204   1   236.204   50.794   < .001   0.146   0.154   
Sex at Birth   65.714   1   65.714   14.131   < .001   0.041   0.048   
Residuals   1292.761   278   4.650             
Note.  Type III Sum of Squares  
 
 
Combined with the results from the Test set analyses, the results of these analyses 
suggested that an association does not exist between either CV risk factor and 
proportional measures of total gray and white matter volume. 
Validation set summary. Table 6 summarizes the results of Validation set 
analyses.  TxHxHypertension was associated with performance on Verbal Fluency, Digit 
Symbol Coding, and Similarities across models using raw scores and RBN. No NP 
measures were associated with TxHxLipids and no volumetric measures of brain matter 
volume were associated with CV risk factors.  These results were broadly consistent with 
the results of the Test set analyses; however, of the four analyses of Verbal Fluency 
performance, only the Test set raw score analysis found no evidence of a meaningful 
association between TxHxHypertension and NP performance.  Because of inconsistent 
support, it cannot be concluded that Verbal Fluency is associated with TxHxHypertension 
based on these analyses.  Effect sizes within meaningful associations remained small 




Summary of Test and Validation Dataset Analyses 
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 The primary aim of this study was to examine the relation between key domains 
of cognition and indirect markers of CV risk in a community sample where individuals 
were grouped according to medication treatment history.  Memory is both a highly 
circumscribed cognitive operation located within the temporal lobes, and generally 
considered to be the earliest cognitive sign of dysfunction (Jack et al., 2013).  As such, a 
potential finding was that only memory would be associated with CV risk.  Other 
cognitive functions, such as executive functioning and lexical access, are couched within 
neural networks that are more broadly distributed throughout the brain.  Because of the 
diffuse impact of CV factors on whole brain functionality, findings of impairment in one 
or both of these domains was also a possibility, and may have occurred without or 
without corresponding impairment on measures of memory.  As such, all, some, or none 
of these domains may have been impacted by CV influences on neuronal function, and 
that pattern is informative about how CV risk can factor into risk for cognitive decline. 
Of the six NP measures tested for associations, only two measures evidenced an 
association with medication treatment history.  Associations between measures of 
processing speed/graphomotor functioning and of naming/lexical access were observed 
with participants who were treated for hypertension across both an initial Test study 
sample and within a secondary Validation study sample. Participants who were treated 
for hypertension scored lower on both tests compared to participants without treatment 
history.  Effect sizes for these associations were small, explaining less than 5% of 




however, the conclusion that these associations are meaningful is supported both by the a 
priori assumption that participants drawn from a community sample are without 
clinically significant impairment, and by the broadly consistent findings between the 
independently analyzed Test and Validation sample groups. 
Meaningful relations were restricted to treatment history for hypertension and no 
meaningful associations were found between domains of cognition and treatment history 
for hyperlipidemia.  Additionally, no meaningful interactions between studied CV risk 
factors were observed, counter to expectations stated in Hypothesis 1b. Further, no 
measure of episodic memory was observed to be associated with CV risk factors.  This 
preempted the assumptions of Hypothesis 1c, which indicated that visual episodic 
memory would produce a larger effect size compared to verbal episodic memory testing.  
This larger effect size would have supported the hypothesis that a visual measure of 
episodic memory would be more sensitive to impairment related to CV risk factors than 
similar verbal measures.  In all analyses, episodic memory measures were related to 
effect sizes much smaller than 1 percent and were not determined to be meaningfully 
associated with CV risk factors. 
The secondary aim of this study was to identify any concurrent differences in 
whole brain gray and white matter concomitant with performance differences observed 
on neuropsychological testing.  While neuropsychological testing detected differences 
among participant groups with different degrees of history for treatment of hypertension, 






Neuropsychological Performance in the Context of CV Risk 
 In the present study, evidence was found supporting an association between an 
established history of intervention with medication typically prescribed to address 
hypertension and cognitive performance on NP tests sensitive to deficits affecting 
relatively non-localizing neurocognitive networks.  Within these associations, individuals 
who were consistently treated for hypertension scored lower. 
The Digit Symbol subtest is well-known to be a sensitive measure to 
neuropsychological impairment (González-Blanch et al., 2011; Joy, Kaplan, & Fein, 
2004).  Successful performance requires a range of cognitive operations including motor 
control, visual scanning, and incidental learning.  In this research, we were not able to 
disambiguate between all three of these domains; nonetheless, one or some combination 
of these cognitive operations likely negatively impacted test performance.  Between-
group performance differed across all levels of treatment history for hypertension.  
Reduced output on this task in the context of CV risk suggests these cognitive operations 
may be among the earliest cognitive signs of a potentially pernicious cognitive 
consequence related to CV risk.  
The Similarities test is a measure of verbal concept formation requiring 
participants to provide the superordinate concept for word pairs.  There are a variety of 
cognitive operations that underlie performance, including problem solving and word 
finding/lexical access.  A reduced score on this test indicates a greater occurrence of 
concrete (and therefore less superordinate) responses, reflecting some incapacity to find 
an optimal abstract response.  It is possible that subtle to mild word finding difficulty 




help to disambiguate the nature of the underlying impairment observed.  For test items 
that yielded less than an optimal response, participants could be queried with a multiple 
choice.  The extent to which participants benefit from multiple choice cuing can clarify 
the involvement of word finding issues in yielding reduced Similarities performance, 
compared to a true reduction in ability to extrapolate to a superordinate connection (see 
WAIS-R NI; Kaplan, Fein, Morris, & Delis, 1991 for an example of this administration). 
As noted above, word finding and graphomotor processing do not necessarily 
localize to a single brain region.  By contrast, episodic memory is well-known to be 
mediated and localized to medial temporal lobe brain regions.  In dementia syndromes 
such as AD, episodic memory is often viewed as the earliest and most prominent area of 
cognitive disability.  To the extent that CV disease contributes to dementia syndromes, 
these data suggest that word finding and graphomotor processing may be early signs of 
cognitive impairment.  As well, tests of episodic memory and measures that access 
cognitive functions rooted in more circumscribed brain regions did not demonstrate 
sensitivity to potential impairment.  
The nature of cognitive impairment assessment is one of sensitivity to impairment 
in general vs specificity that implicates a particular neurocognitive network.  Results 
significant for episodic memory would have indicated a specific neurocognitive network 
involving the temporal lobe and the hippocampus, which has been linked to memory and 
AD (Den Heijer et al., 2012).  However, the results of the present study identified 
impairment only on tests of lexical access and processing speed, which can occur in the 
context of any kind of cognitive impairment, regardless of cause.  While detectable with 




signs of cognitive deficits are both mild and diverse, appearing most clearly on measures 
that access multiple domains of cognitive function. 
Downstream Cognition in the Context of CV Intervention 
 Among individuals taking medication commonly prescribed to address 
hypertension, and without significant differences in measures of blood pressure, small but 
identifiable differences in performance on NP measures were observed. Consequently, 
this study indicates that interventions designed to address risk factors for CV disease, 
while generally successful at managing CV risk, do not prevent downstream 
neurocognitive dysfunction. 
 The absence of meaningful findings with respect to lipid modifying agents offers 
valuable insight into the value of assessing CV treatment history as a potential marker for 
cognitive decline and the possible subsequent emergence of a dementia illness.  The 
independent variables employed in this study were constructed from the participant’s 
demonstrated history of treatment with medication typically prescribed for hypertension 
and hyperlipidemia. Importantly, hypertension and hyperlipidemia, while frequently 
comorbid, are distinct conditions with diverse treatment plans and considerations.  In 
particular, hypertensive medication is typically prescribed in the presence of elevated 
blood pressure levels or when a family history indicates an increased risk for elevated 
pressure (Jarraya, 2017).  Conversely, lipid-modifying medication, in particular statin 
drugs, are often a valuable, proactive treatment begun on the basis of a patient’s age 
(Silverman & Schmeidler, 2018), rather than in the context of specific risk indications.   
As such, as a marker of underlying CV risk, treatment with lipid modifying agents 




underlying condition, but in how aggressive their primary care physician chooses to be 
with respect to cholesterol management.  In contrast, while antihypertensive medications 
have some off-label usages, which may contribute to their use by individuals without 
concern for high blood pressure, it is highly unlikely to encounter an individual with 
untreated hypertension (Ang et al., 2020).  The presence of observed group-based 
differences with respect to neuropsychological performance among hypertension 
treatment history groups supports the theoretical value of this indirect marker of CV risk.   
Neuroanatomical Substrates of Impairment 
While the present study reports associations between NP testing and treatment 
history for hypertension, no corresponding associations were found for treatment history 
and same-day volumetric measures of gray and white matter on MRI.  The absence of 
meaningful findings associating MRI and hypertension treatment is surprising in the 
context of the pervading model of biomarkers of AD.  
A prevailing model proposed by Jack and colleagues (2013) attempts to describe 
the chronology in which markers of AD present and thereafter become detectable.  The 
presence of amyloid beta peptides (Aβ) in cerebrospinal fluid or positron emission 
tomography imaging is hypothesized to be among the earliest biomarkers signaling the 
emergence of dementia such as Alzheimer’s disease; followed, perhaps by other 
pathophysiological and anatomical alterations.  Thus the predominant model of AD 
biomarkers suggests that volumetric changes should precede cognitive changes.  More 
intuitively, cognitive deficits likely either co-occur or precede detectable organic changes 




 Although the model proposed by Jack and colleagues has been revised since the 
original publication (Jack et al., 2010) to de-emphasize the temporal relations between 
biomarkers, the updated model maintains that cognitive impairment does not emerged 
before biological signs of pathology. In part, this emphasis on concrete signs of 
physiological alterations reflects the underutilization of measures that may be particularly 
sensitive to neuropsychological impairment.    
Wider adoption of digital assessment technology might provide a means to 
reliably measure behaviors that are difficult to quantify, including linguistic and acoustic 
markers that may be extracted for speech and verbal test responses and highly nuanced 
graphomotor output.  Emerging research in digital technologies and process-based NP 
testing (Binaco et al., 2020; Emrani et al., 2018, 2019; Piers et al., 2017; Wasserman et 
al., 2019, 2020) continue to indicate that subtle cognitive performance markers may soon 
move the cognitive marker curve further to the left of the AD pathology cascade model. 
CV Risk and Insidious Dementia 
CV risk is associated with the emergence of insidious onset dementia. 
Hyperlipidemia and hypertension act upon blood vessels in the brain and heart, such that 
having one condition or the other would indicate a vasculopathy, in which the vessel may 
be narrowed by plaque or a disturbance in the hemodynamics of blood flow due to 
pressure. Regardless of the phenotype, these conditions within the blood vessels may 
result in reduction in brain profusion such that blood may not necessarily consistently 





Concomitant with fluctuating conditions with the vessel, deterioration of the 
blood-brain barrier can contribute to a greater accumulation of molecules in the brain that 
are damaging to neuronal function, as well as reducing the ability to regulate and clear 
these substances.  The blood-brain barrier is composed of endothelial cells, pericytes, 
vascular smooth muscle cells, glia and neurons, that together act to control blood-brain 
barrier permeability and blood flow.  Microstructural changes found in pericytes (e.g. 
intracellular inclusions, large lipid granules) correlate with capillary reduction, dilation of 
vessels, and the appearance of tortuous vessels (Hughes & Craft, 2016; Nelson, Sweeney, 
Sagare, & Zlokovic, 2016; Sweeney, Sagare, & Zlokovic, 2015), indicating a pathway by 
which CV risk factors result in reduced cerebral perfusion.    
This two-hit vascular hypothesis (Zlokovic, 2011) asserts that vascular risk 
factors and cerebrovascular damage (hit 1) is the primary insult that has a causal 
sequence promoting blood-brain barrier dysfunction and reduction in cerebral blood flow, 
ultimately leading to accumulation of Aβ and other neuropathology in the brain 
associated with AD (hit 2).  This model describes two pathways: 1.) a nonamyloid-β 
pathway, in which circulating neurotoxic molecules (e.g. thrombin, plasminogen, 
fibrinogen) and hypoperfusion induce early neuronal dysfunction; and 2.) an 
amyloidogenic Aβ pathway, in which Aβ clearance is derailed by blood-brain barrier 
dysfunction.  This results in overexpression and enhanced processing of amyloid 
precursor protein, which can promote Aβ accumulation.  The increase in Aβ (hit 2) 
amplifies neuronal dysfunction and accelerates the neurodegenerative processes of AD.  




regulating cerebral circulation, and perpetuating vascular dysfunction and 
neuropathology. 
The current study can only hypothesize about the involvement of blood-brain 
barrier breach in explaining the observed associations between NP measures of 
processing speed and lexical access and CV risk in the absence of anatomical differences 
in structural brain MRI.  Further study involving clinical samples and use of serum-based 
markers of blood-brain barrier deterioration will expand on the available evidence that 
explains the aetiology of cognitive changes relating to CV risk factors. 
Regression-Based Norms  
Use of RBN methods enables the cross-comparison of measure performance with 
differing qualities and characteristics, as well as allowing an individual’s performance to 
be viewed within the context of the demographic factors that are known to, in part, 
impact performance.  However, NP measures are not immune to cultural or functional 
biases (Fastenau, 1998; Strauss, Sherman, & Spreen, 2006), and normative scores allow 
for the ready evaluation of performance within the accepted paradigm that these biases 
have yet to be fully expunged (Duff & Ramezani, 2015; Oosterhuis et al., 2016; Shirk et 
al., 2011).   
 For the present study, RBNs were constructed based on accounting for the 
normative impact of age, education, and sex at birth on NP performance.  Each analysis 
of RBN-based performance measures employing the Test and Validation data sets was 
repeated in an ANCOVA model using the raw score performance measure and for which 




of repeated analyses across the 12 analysis pairs (6 Test set pairs, 6 Validation set pairs) 
consistently yielded equivalent measures of statistical significance and effect size.  
In the case of Test set analyses of raw score and RBN Verbal Fluency, only the 
RBN analysis returned a meaningful effect size.  While this was not the case for the 
Validation set, in which both analyses supported the presence of a relation between 
treatment history for hypertension and Verbal Fluency performance, several factors may 
explain the contrasting outcomes of analysis with these two methods.  
Firstly, the Test data set analyses involved the refinement of the model through 
the exclusion of non-meaningful interaction and covariate terms.  For the Verbal Fluency 
analysis, sex at birth was excluded from the final model due to low effect size and non-
significant p-value at an alpha level of .05. This differed from the design of the RBN 
performance score, in which sex at birth was retained in the model.  Given that the effect 
sizes for NP performance was small across most analyses, never rising about 4%, it is 
possible that the exclusion of sex at birth resulted in other covariates absorbing variance 
that would otherwise have been attributed to the independent variables, particularly 
treatment history for hypertension.  
Secondly, although one benefit of an RBN approach is that performance on NP 
measures is articulated as a continuous scale, rather than a discrete partition such as 
scaled scores (Lenhard et al., 2018), education as a covariate is typically recorded in non-
continuous terms, often either as a grade-year equivalence scale or a rank-order diploma 
scale.  The education variable available for these data was based on a rank-order diploma 
scale, compressing all possible education outcomes into only four potential categories: 1. 




college.”  As a consequence, the treatment of this important demographic factor as an 
ordinal variable may have obscured important, subtle contributions of education, which 
may have impacted both the raw score and RBN performance analyses, contributing to 
inconsistent findings.  
Lastly, although the intention of this analytic approach was to reduce the potential 
of an erroneous finding through minimizing the total number of independent analyses 
performed, the final design resulted in 24 general linear models being tested for six NP 
dependent variables (6 Test set raw score, 6 Test set RBN, 6 Validation set raw score, 6 
Validation set RBN).  It is not unexpected that some analyses would return conflicting 
findings.  In the case of Verbal Fluency, three of the four analyses performed with this 
dependent variable yielded meaningful associations with treatment history for 
hypertension.  Nonetheless, the decision was made to not conclude a relation between CV 
risk and Verbal Fluency on the basis of these data. It was anticipated at the outset of the 
study that meaningful relations would withstand repeated analyses with two independent 
datasets (Test and Validation).  While other measures meaningfully met this standard 
(Digit Symbol Coding and Similarities), inconsistent findings for Verbal Fluency indicate 
that further validation with a unrelated sample is necessary before further conclusions can 
be drawn. 
Strengths and Limitations 
 The strengths of the present study include the use of a prestigious and trusted data 
set drawing on a healthy, community dwelling, independently functioning population 
without cognitive impairment.  These analyses employ commonly administered tests of 




CV risk.  The methodology is structured to include several self-validation procedures, 
including repeat analyses of dependent variables based upon raw score performance and 
RBN performance, as well as replication in a hold-out sample.  Decisions about 
meaningful findings were based on both a standard statistical decision criteria (alpha = 
.05) as well as a theoretically informed judgment considering the relative effect sizes of 
variables and between-group differences.  In all cases in which a meaningful relation was 
concluded to exist, these indicators were in agreement. 
The present study is not without limitations, many of which have already been 
discussed in detail, including the non-continuous nature of the education history variable 
used in these analyses and the limited ability to account for potential instances of 
polypharmacy.  The homogeneity of the FHS sample limits the ability to generalize these 
results to demographically distinct groups.  These results are best understood to describe 
the relation between medication usage for CV risk factors and cognitive performance 
among white individuals of middle age and older originating in the northeastern region of 
the United States.  Efforts to expand on the current study would benefit from exploring a 
more racially and regionally diverse sample, as well as employing a less-restricted 
measure of educational attainment.  
Conclusion 
 Medication history shows promise as an indirect measure of cardiovascular risk 
when assessing for cognitive impairment related to insidious onset dementia.  
Neuropsychological measures sensitive to diffuse cognitive change can detect small but 
present differences in performance among individuals with a consistent history of 




and older adults in a community sample.  Crucially, these differences are detectable in the 
presence of monitored and well-controlled blood pressure, indicating that downstream 
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Tables and Figures of Additional Demographics 
Table A1 
Mean Blood Pressure Values for Hypertension Treatment History Groups 
Mean Blood Pressure Values for Hypertension 
Treatment History Groups N Mean Std. Deviation 
Average systolic blood 
pressure (mmHg), Exam 9 
Never Treated 374 123.12 14.755 
Partially Treated 170 125.80 15.515 
Fully Treated 516 128.83 16.633 
Total 1060 126.33 16.011 
Average diastolic blood 
pressure (mmHg), Exam 9 
Never Treated 374 72.95 8.644 
Partially Treated 170 72.42 9.149 
Fully Treated 516 69.65 9.781 
Total 1060 71.26 9.418 
 
Table A2 
Mean Cholesterol Values for Lipid Treatment History Groups 
Mean Cholesterol Values for Lipid Treatment 
History Groups N Mean Std. Deviation 
HDL cholesterol (mg/dL), 
Exam 9 
Never Treated 319 67.12 18.758 
Partially Treated 251 64.28 19.059 
Fully Treated 480 58.75 17.112 
Total 1050 62.62 18.456 
Calculated LDL 
cholesterol (mg/dL), Exam 
9 
Never Treated 318 110.30 25.224 
Partially Treated 251 102.83 33.076 
Fully Treated 479 88.26 27.010 























































Analysis of Variance Tables of Test Dataset Final Models 
Table B1 
 
RBN Boston Naming Test Model 
 
ANOVA – RBN BNT Model 
Cases  Sum of Squares  df  Mean Square  F  p  η²  η² p  
TxHxHypertension   1.147  2   0.573   0.358   0.699   0.001   0.001   
TxHxLipids   3.209  2   1.605   1.003   0.367   0.003   0.003   
Residuals   1102.344   689   1.600             
Note.  Type III Sum of Squares  
Interaction term excluded 
 
Mean Differences Between Groups – RBN BNT Model 
 95% Confidence 
Interval  
 
Variable  Comparison  Difference  Lower  Upper  Cohen's d  
TxHxHypertension   
Never Treated-Consistently 
Treated  
 0.082   -0.412   0.575   0.064   
  Inconsistently Treated-
Consistently Treated  
 0.095   -0.257   0.447   0.075   
    
Inconsistently Treated-
Never Treated  
 0.013   -0.456   0.483   0.011   
TxHxLipids   
Never Treated-Consistently 
Treated  
 0.147   -0.290   0.583   0.116   
  Inconsistently Treated-
Consistently Treated  
 0.142   -0.232   0.516   0.112   
    Inconsistently Treated-
Never Treated  








Raw Score Boston Naming Test Model 
 
ANCOVA – Raw Scores BNT Model 
Cases  Sum of Squares  df  Mean Square  F  p  η²  η² p  
TxHxHypertension   10.312   2   5.156   1.863   0.157   0.009   0.010   
TxHxLipids   2.843   2   1.422   0.514   0.599   0.003   0.003   
Age  42.317   1   42.317   15.292   < .001   0.038   0.041   
Education   56.200   1   56.200   20.310   < .001   0.051   0.054   
Residuals   993.417   359   2.767             
Note.  Type III Sum of Squares  
Interaction term and sex at birth excluded 
 
Mean Differences Between Groups  
 95% Confidence 
Interval  
 
Variable  Comparison  Difference  Lower  Upper  Cohen's d  
TxHxHypertension   Never Treated-Consistently 
Treated  
 -0.050   -0.889   0.789   -0.023   
  Inconsistently Treated-
Consistently Treated  
 0.070   -0.529   0.669   0.033   
    
Inconsistently Treated-
Never Treated  
 0.120   -0.678   0.918   0.056   
TxHxLipids   
Never Treated-Consistently 
Treated  
 0.056   -0.685   0.798   0.026   
  Inconsistently Treated-
Consistently Treated  
 0.130   -0.506   0.766   0.060   
    
Inconsistently Treated-
Never Treated  






Table B3  
 
RBN Similarities Model 
 
ANOVA – RBN Similarities Model 
Cases  Sum of Squares  df  Mean Square  F  p  η²  η² p  
TxHxHypertension   15.430  2   7.715   5.958   0.003   0.016   0.016   
TxHxLipids   0.948  2   0.474   0.366   0.694   0.001   0.001   
Residuals   925.847   715   1.295             
Note.  Type III Sum of Squares  
Interaction term excluded 
 
Mean Differences Between Groups – RBN Similarities Model 
 95% Confidence 
Interval  
 
Variable  Comparison  Difference  Lower  Upper  Cohen's d  
TxHxHypertension   
Never Treated-Consistently 
Treated  
 0.330   -0.107   0.768   0.290   
  Inconsistently Treated-
Consistently Treated  
 0.253   -0.057   0.563   0.222   
    Inconsistently Treated-
Never Treated  
 -0.077   -0.495   0.340   -0.068   
TxHxLipids   
Never Treated-Consistently 
Treated  
 -0.017   -0.400   0.366   -0.015   
  Inconsistently Treated-
Consistently Treated  
 0.076   -0.254   0.407   0.067   
    
Inconsistently Treated-
Never Treated  







Table B4  
 
Raw Score Similarities Model 
 
ANCOVA – Raw Score Similarities Model 
Cases  Sum of Squares  df  Mean Square  F  p  η²  η² p  
TxHxHypertension   67.162   2   33.581   3.281   0.038   0.007   0.009   
TxHxLipids   2.004   2   1.002   0.098   0.907   2.146e -4   2.738e -4   
Age   117.570   1   117.570   11.489   < .001   0.013   0.016   
Education   1832.576   1   1832.576   179.075   < .001   0.196   0.200   
Residuals   7317.008   715   10.234              
Note.  Type III Sum of Squares  
Interaction term and sex at birth excluded 
 
Mean Differences Between Groups – Raw Scores Similarities Model 
 95% Confidence 
Interval  
 
Variable  Comparison  Difference  Lower  Upper  Cohen's d  
TxHxHypertension   Never Treated-Consistently 
Treated  
 0.710   -0.515   1.935   0.223   
  Inconsistently Treated-
Consistently Treated  
 0.609   -0.258   1.476   0.191   
    
Inconsistently Treated-
Never Treated  
 -0.101   -1.271   1.069   -0.032   
TxHxLipids   
Never Treated-Consistently 
Treated  
 -0.121   -1.191   0.950   -0.038   
  Inconsistently Treated-
Consistently Treated  
 -0.004   -0.929   0.922   -0.001   
    
Inconsistently Treated-
Never Treated  







RBN Digit Symbol Coding Model 
 
ANOVA – RBN Digit Symbol Coding Model  
Cases  Sum of Squares  df  Mean Square  F  p  η²  η² p  
TxHxHypertension   9.669   2   4.835   4.683   0.010   0.014   0.014   
TxHxLipids   1.356   2   0.678   0.657   0.519   0.002   0.002   
Residuals   665.871   645   1.032             
Note.  Type III Sum of Squares  
Interaction term excluded 
 
Mean Differences Between Groups – RBN Digit Symbol Coding Model 
 95% Confidence 
Interval  
 
Variable  Comparison  Difference  Lower  Upper  Cohen's d  
TxHxHypertension   
Never Treated-Consistently 
Treated  
 0.267   -0.137   0.671   0.263   
  Inconsistently Treated-
Consistently Treated  
 0.237   -0.054   0.527   0.233   
    Inconsistently Treated-
Never Treated  
 -0.030   -0.419   0.359   -0.030   
TxHxLipids   
Never Treated-Consistently 
Treated  
 0.113   -0.248   0.473   0.111   
  Inconsistently Treated-
Consistently Treated  
 0.035   -0.275   0.345   0.035   
    
Inconsistently Treated-
Never Treated  








Raw Score Digit Symbol Coding Model 
 
ANCOVA – Raw Score Digit Symbol Coding Model 
Cases  Sum of Squares  df  Mean Square  F  p  η²  η² p  
TxHxHypertension   1219.650   2   609.825   4.797   0.009   0.012   0.015   
TxHxLipids   191.115   2   95.558   0.752   0.472   0.002   0.002   
Age   14354.168   1   14354.168   112.901   < .001   0.136   0.150   
Education   3513.599   1   3513.599   27.636   < .001   0.033   0.041   
Sex at Birth   4425.942   1   4425.942   34.812   < .001   0.042   0.051   
Residuals   81623.590   642   127.140             
Note.  Type III Sum of Squares  
Interaction term excluded 
 
Mean Differences Between Groups – Raw Score Digit Symbol Coding Model  
 95% Confidence 
Interval  
 
Variable  Comparison  Difference  Lower  Upper  Cohen's d  
TxHxHypertension   
Never Treated-Consistently 
Treated  
 3.138   -1.346   7.622   0.278   
  Inconsistently Treated-
Consistently Treated  
 2.791   -0.434   6.015   0.247   
    
Inconsistently Treated-
Never Treated  
 -0.347   -4.667   3.972   -0.031   
TxHxLipids   
Never Treated-Consistently 
Treated  
 1.372   -2.629   5.372   0.122   
  Inconsistently Treated-
Consistently Treated  
 0.446   -2.994   3.886   0.040   
    Inconsistently Treated-
Never Treated  
 -0.926   -4.630   2.778   -0.082   








RBN Verbal Fluency Model 
 
ANOVA – RBN Verbal Fluency Model 
Cases  Sum of Squares  df  Mean Square  F  p  η²  η² p  
TxHxHypertension   0.842   2   0.421   5.637   0.004   0.016   0.016   
TxHxLipids   0.281   2   0.141   1.884   0.153   0.005   0.005   
Residuals   51.876   695   0.075             
Note.  Type III Sum of Squares  
Interaction term excluded 
 
Mean Differences Between Groups – RBN Verbal Fluency Model 
 95% Confidence 
Interval  
 
Variable  Comparison  Difference  Lower  Upper  Cohen's d  
TxHxHypertension   
Never Treated-
Inconsistently Treated  
 -0.033   -0.138   0.073   -0.119   
  Consistently Treated-
Inconsistently Treated  
 -0.092   -0.167   -0.017   -0.337   
    Consistently Treated-Never 
Treated  
 -0.059   -0.160   0.041   -0.218   
TxHxLipids   
Never Treated-Consistently 
Treated  
 0.028   -0.065   0.121   0.103   
  Inconsistently Treated-
Consistently Treated  
 0.051   -0.030   0.131   0.185   
    
Inconsistently Treated-
Never Treated  








Raw Score Verbal Fluency Model 
 
ANCOVA – Raw Score Verbal Fluency Model  
Cases  Sum of Squares  df  Mean Square  F  p  η²  η² p  
TxHxHypertension   667.126   2   333.563   2.409   0.091   0.006   0.007   
TxHxLipids   196.718   2   98.359   0.710   0.492   0.002   0.002   
Age   2503.217   1   2503.217   18.078   < .001   0.023   0.025   
Education   7119.014   1   7119.014   51.411   < .001   0.067   0.069   
Residuals   96099.105   694   138.471             
Note.  Type III Sum of Squares  
Interaction term and sex at birth excluded 
 
Mean Differences Between Groups – Raw Score Verbal Fluency Model 
 95% Confidence 
Interval  
 
Variable  Comparison  Difference  Lower  Upper  Cohen's d  
TxHxHypertension   Never Treated-
Inconsistently Treated  
 -2.219   -6.748   2.310   -0.188   
  Consistently Treated-
Inconsistently Treated  
 -2.980   -6.226   0.266   -0.253   
    
Consistently Treated-Never 
Treated  
 -0.761   -5.105   3.582   -0.065   
TxHxLipids   
Never Treated-Consistently 
Treated  
 0.258   -3.752   4.268   0.022   
  Inconsistently Treated-
Consistently Treated  
 1.306   -2.156   4.767   0.111   
    
Inconsistently Treated-
Never Treated  









RNB Logical Memory Delayed Free Recall Model 
 
ANOVA – RNB Logical Memory Delayed Free Recall Model  
Cases  Sum of Squares  df  
Mean 
Square  F  p  η²  η² p  
TxHxHypertension   2.782   2   1.391   1.366   0.256   0.004   0.004   
TxHxLipids   1.319   2   0.659   0.648   0.523   0.002   0.002   
Residuals   719.632   707   1.018             
Note.  Type III Sum of Squares  
Interaction term excluded 
 
Mean Differences Between Groups – RNB Logical Memory Delayed Free Recall 
Model 
 95% Confidence 
Interval  
 
Variable  Comparison  Difference  Lower  Upper  Cohen's d  
      










 0.030   -0.245   0.306   0.030   




 0.144   -0.231   0.519   0.143   










 0.110   -0.184   0.405   0.109   












Raw Score Logical Memory Delayed Free Recall Model 
 
ANCOVA – Raw Score Logical Memory Delayed Free Recall Model  
Cases  Sum of Squares  df  Mean Square  F  p  η²  η² p  
TxHxHypertension   51.066   2   25.533   1.993   0.137   0.005   0.006   
TxHxLipids   13.226   2   6.613   0.516   0.597   0.001   0.001   
Age   269.078   1   269.078   20.999   < .001   0.027   0.029   
Education   549.517   1   549.517   42.884   < .001   0.055   0.057   
Sex at Birth   166.099   1   166.099   12.962   < .001   0.016   0.018   
Residuals   9021.086   704   12.814             
Note.  Type III Sum of Squares  
Interaction term excluded 
 
Mean Differences Between Groups – Raw Score Logical Memory Delayed Free 
Recall Model 
 95% Confidence 
Interval  
 
Variable  Comparison  Difference  Lower  Upper  Cohen's d  
            
TxHxHypertension   Never Treated-
Inconsistently Treated  
 -0.495  -1.885  0.896  -0.138  
  
Consistently Treated-
Inconsistently Treated   0.131  -0.848  1.109  0.037  
    
Consistently Treated-Never 
Treated  
 0.626  -0.704  1.955  0.175  
TxHxLipids   
Never Treated-Consistently 
Treated  
 0.013   -1.197   1.223   0.004   
  Inconsistently Treated-
Consistently Treated  
 0.352   -0.693   1.397   0.098   
    
Inconsistently Treated-
Never Treated  








RBN Visual Reproduction Delayed Free Recall Model 
 
ANOVA – RBN Visual Reproduction Delayed Free Recall Model  
Cases  Sum of Squares  df  Mean Square  F  p  η²  η² p  
TxHxHypertension   4.671   2   2.335   2.206   0.111   0.006   0.006   
TxHxLipids   2.252   2   1.126   1.064   0.346   0.003   0.003   
Residuals   754.869   713   1.059             
Note.  Type III Sum of Squares  
Interaction term excluded 
 
Mean Differences Between Groups – RBN Visual Reproduction Delayed Free 
Recall Model 
 95% Confidence 
Interval  
 
Variable  Comparison  Difference  Lower  Upper  Cohen's d  
TxHxHypertension   Never Treated-
Inconsistently Treated  
 -0.149   -0.543   0.245   -0.145   
  Consistently Treated-
Inconsistently Treated  
 -0.239   -0.519   0.042   -0.232   
    
Consistently Treated-Never 
Treated  
 -0.090   -0.466   0.287   -0.087   
TxHxLipids   
Never Treated-Consistently 
Treated  
 -0.090   -0.438   0.257   -0.088   
  Inconsistently Treated-
Consistently Treated  
 0.063   -0.236   0.362   0.061   
    
Inconsistently Treated-
Never Treated  








Raw Score Visual Reproduction Delayed Free Recall Model 
 
ANCOVA – Raw Score Visual Reproduction Delayed Free Recall Model  
Cases  Sum of Squares  df  Mean Square  F  p  η²  η² p  
TxHxHypertension   36.130   2   18.065   2.511   0.082   0.006   0.007   
TxHxLipids   13.533   2   6.767   0.941   0.391   0.002   0.003   
Age   549.893   1   549.893   76.441   < .001   0.092   0.097   
Education   252.441   1   252.441   35.092   < .001   0.042   0.047   
Residuals   5114.680   711   7.194             
Note.  Type III Sum of Squares  
Interaction term and Sex at Birth excluded 
 
Mean Differences Between Groups – Raw Score Visual Reproduction Delayed Free 
Recall Model 
 95% Confidence 
Interval  
 
Variable  Comparison  Difference  Lower  Upper  Cohen's d  
TxHxHypertension   
Never Treated-
Inconsistently Treated  
 -0.401  -1.427  0.624  -0.150  
  
Consistently Treated-
Inconsistently Treated  
 -0.692  -1.423  0.038  -0.258  
    Consistently Treated-Never 
Treated  
 -0.291  -1.271  0.689  -0.109  
TxHxLipids   
Never Treated-Consistently 
Treated  
 -0.202   -1.106   0.702   -0.075   
  Inconsistently Treated-
Consistently Treated  
 0.160   -0.619   0.938   0.060   
    
Inconsistently Treated-
Never Treated  








Total Percentage Gray Matter Volume Model 
 
ANCOVA – Total Percentage Gray Matter Volume Model 
Cases  Sum of Squares  df  Mean Square  F  p  η²  η² p  
TxHxHypertension   5.696   2   2.848   1.158   0.315   0.003   0.004   
TxHxLipids   4.663   2   2.331   0.948   0.388   0.003   0.004   
Age   343.040   1   343.040   139.504   < .001   0.192   0.208   
Sex at Birth   131.263   1   131.263   53.381   < .001   0.073   0.091   
Residuals   1305.730   531   2.459             
Note.  Type III Sum of Squares  
Interaction term and Education excluded 
 
Mean Differences Between Groups – Total Percentage Gray Matter Volume Model 
 95% Confidence 
Interval  
 
Variable  Comparison  Difference  Lower  Upper  Cohen's d  
TxHxHypertension   Never Treated-Consistently 
Treated  
 0.241   -0.439   0.922   0.154   
  Inconsistently Treated-
Consistently Treated  
 0.046   -0.446   0.538   0.029   
    
Inconsistently Treated-
Never Treated  
 -0.195   -0.854   0.463   -0.125   
TxHxLipids   
Never Treated-Consistently 
Treated  
 -0.206   -0.815   0.402   -0.132   
  Inconsistently Treated-
Consistently Treated  
 0.011   -0.516   0.538   0.007   
    
Inconsistently Treated-
Never Treated  








Total Percentage White Matter Volume Model 
 
ANCOVA – Total Percentage White Matter Volume Model  
Cases  Sum of Squares  df  Mean Square  F  p  η²  η² p  
TxHxHypertension   3.273   2   1.637   0.403   0.668   0.001   0.002   
TxHxLipids   1.052   2   0.526   0.130   0.878   < .001   < .001  
Age   381.432   1   381.432   93.958   < .001   0.148   0.150   
Sex at Birth   41.956   1   41.956   10.335   0.001   0.016   0.019   
Residuals   2155.645   531   4.060              
Note.  Type III Sum of Squares  
Interaction term and Education excluded 
 
Mean Differences Between Groups – Total Percentage White Matter Volume Model 
 95% Confidence 
Interval  
 
Variable  Comparison  Difference  Lower  Upper  Cohen's d  
TxHxHypertension   Never Treated-Consistently 
Treated  
 0.111   -0.763   0.986   0.055   
  Inconsistently Treated-
Consistently Treated  
 0.227   -0.406   0.859   0.113   
    
Inconsistently Treated-
Never Treated  
 0.115   -0.731   0.962   0.057   
TxHxLipids   
Never Treated-Consistently 
Treated  
 0.094   -0.688   0.876   0.047   
  Inconsistently Treated-
Consistently Treated  
 0.093   -0.584   0.770   0.046   
    Inconsistently Treated-
Never Treated  







Added Variable Plots of Test Dataset Final Models 
 












Figure C3. Raw Score BNT Added Variable Plot of TxHxHypertension after Accounting 





Figure C4. Raw Score BNT Added Variable Plot of TxHxLipids after Accounting for 





Figure C5.  RBN Similarities Added Variable Plot of TxHxHypertension after 











Figure C7. Raw Score Similarities Added Variable Plot of TxHxHypertension after 





Figure C8. Raw Score Similarities Added Variable Plot of TxHxLipids after Accounting 





Figure C9. RBN Digit Symbol Coding Added Variable Plot of TxHxHypertension after 





Figure C10. RBN Digit Symbol Coding Added Variable Plot of TxHxLipids after 





Figure C11. Raw Score Digit Symbol Coding Added Variable Plot of TxHxHypertension 





Figure C12. Raw Score Digit Symbol Coding Added Variable Plot of TxHxLipids after 





Figure C13. RBN Verbal Fluency Added Variable Plot of TxHxHypertension after 





Figure C14. RBN Verbal Fluency Added Variable Plot of TxHxLipids after Accounting 





Figure C15. Raw Score Verbal Fluency Added Variable Plot of TxHxHypertension after 





Figure C16. Raw Score Verbal Fluency Added Variable Plot of TxHxLipids after 





Figure C17. RBN Logical Memory Delayed Free Recall Added Variable Plot of 





Figure C18. RBN Logical Memory Delayed Free Recall Added Variable Plot of 





Figure C19. Raw Score Logical Memory Delayed Free Recall Added Variable Plot of 





Figure C20. Raw Score Logical Memory Delayed Free Recall Added Variable Plot of 





Figure C21. RBN Visual Reproduction Delayed Free Recall Added Variable Plot of 





Figure C22. RBN Visual Reproduction Delayed Free Recall Added Variable Plot of 





Figure C23. Raw Score Visual Reproduction Delayed Free Recall Added Variable Plot 






Figure C24. Raw Score Visual Reproduction Delayed Free Recall Added Variable Plot 





Figure C25. Total Percentage Gray Matter Volume Added Variable Plot of 





Figure C26. Total Percentage Gray Matter Volume Added Variable Plot of TxHxLipids 





Figure C27. Total Percentage White Matter Volume Added Variable Plot of 





Figure C28. Total Percentage White Matter Volume Added Variable Plot of TxHxLipids 





Analysis of Variance Tables of Validation Dataset Models 
Table D1  
RBN Boston Naming Test Model 
ANOVA – RBN BNT Model 
Cases  Sum of Squares  df  
Mean 
Square  F  p  η²  η² p  
TxHxHypertension   3.730   2   1.865   1.375   0.254   0.009   0.009   
TxHxLipids   5.132   2   2.566   1.892   0.152   0.012   0.012   
Residuals   425.776   314   1.356              
Note.  Type III Sum of Squares   
 
Mean Differences Between Groups – RBN BNT Model 
 95% Confidence 
Interval  
 
Variable  Comparison  Difference  Lower  Upper  Cohen's d  




 0.148   -0.473   0.769   0.127   
  Consistently Treated-
Never Treated  
 -0.151   -0.635   0.333   -0.130   




 -0.299   -0.898   0.300   -0.257   




 -0.020   -0.626   0.587   -0.017   
  Consistently Treated-
Never Treated  
 -0.279   -0.789   0.230   -0.240   













Table D2  
 
Raw Score Boston Naming Test Model 
 
ANCOVA – Raw Score BNT Model 
Cases  Sum of Squares  df  Mean Square  F  p  η²  η² p  
TxHxHypertension   3.964   2   1.982   0.414   0.661   0.002   0.003   
TxHxLipids   2.048   2   1.024   0.214   0.808   0.001   0.001   
Age   142.268   1   142.268   29.702   < .001   0.079   0.086   
Education   145.533   1   145.533   30.383   < .001   0.081   0.088   
Residuals   1508.816   315   4.790             
Note.  Type III Sum of Squares  
 
 
Mean Differences Between Groups – Raw Score BNT Model 
 95% Confidence 
Interval  
 
Variable  Comparison  Difference  Lower  Upper  Cohen's d  
TxHxHypertension   Inconsistently Treated-
Never Treated  
 0.195   -0.964   1.353   0.089   
  Consistently Treated-Never 
Treated  
 -0.049   -0.955   0.857   -0.022   
    
Consistently Treated-
Inconsistently Treated  
 -0.244   -1.361   0.873   -0.111   
TxHxLipids   
Inconsistently Treated-
Never Treated  
 0.046   -1.086   1.178   0.021   
  Consistently Treated-Never 
Treated  
 -0.193   -1.147   0.760   -0.088   
    
Consistently Treated-
Inconsistently Treated  








RBN Similarities Model 
 
ANOVA – RBN Similarities Model 
Cases  Sum of Squares  df  
Mean 
Square  F  p  η²  η² p  
TxHxHypertension   12.970   2   6.485   5.225   0.006   0.031   0.031  
TxHxLipids   0.452   2   0.226   0.182   0.834   0.001   0.001  
Residuals   400.920   323   1.241             
Note.  Type III Sum of Squares  
 
 
Mean Differences Between Groups – RBN Similarities Model 
 95% Confidence 
Interval  
 
Variable  Comparison  Difference  Lower  Upper  Cohen's d  
TxHxHypertension   
Inconsistently Treated-
Never Treated  
 -0.143   -0.728   0.442  -0.128  
  
Consistently Treated-
Never Treated  
 -0.461   -0.918   -0.004  -0.414  
    Consistently Treated-
Inconsistently Treated  
 -0.318   -0.882   0.246  -0.285  
TxHxLipids   
Inconsistently Treated-
Never Treated  
 0.101   -0.465   0.667   0.091   
  Consistently Treated-
Never Treated  
 0.061   -0.420   0.542   0.055   
    
Consistently Treated-
Inconsistently Treated  









Raw Score Similarities Model 
 
ANCOVA – Raw Score Similarities Model 
Cases  Sum of Squares  df  Mean Square  F  p  η²  η² p  
TxHxHypertension   92.726   2   46.363   5.076   0.007   0.025   0.031   
TxHxLipids   9.263   2   4.632   0.507   0.603   0.002   0.003   
Age   91.906   1   91.906   10.062   0.002   0.025   0.030   
Education   611.270   1   611.270   66.923   < .001   0.164   0.173   
Residuals   2931.994   321   9.134             
Note.  Type III Sum of Squares  
 
Mean Differences Between Groups – Raw Score Similarities Model 
 95% Confidence 
Interval  
 
Variable  Comparison  Difference  Lower  Upper  Cohen's d  
TxHxHypertension   
Inconsistently Treated-
Never Treated  




 -1.305  -2.547  -0.063  -0.431  
    Consistently Treated-
Inconsistently Treated  
 -0.989  -2.521  0.543  -0.327  
TxHxLipids   
Inconsistently Treated-
Never Treated  
 0.336   -1.203   1.874   0.111   
  Consistently Treated-Never 
Treated  
 0.467   -0.840   1.773   0.154   
    
Consistently Treated-
Inconsistently Treated  








RBN Digit Symbol Coding Model 
 
ANOVA – RBN Digit Symbol Coding Model  
Cases  Sum of Squares  df  Mean Square  F  p  η²  η² p  
TxHxHypertension   14.203   2   7.102   6.564   0.002   0.042   0.042   
TxHxLipids   1.226   2   0.613   0.566   0.568   0.004   0.004   
Residuals   321.320   297   1.082             
Note.  Type III Sum of Squares  
 
Mean Differences Between Groups – RBN Digit Symbol Coding Model 
 95% Confidence 
Interval  
 
Variable  Comparison  Difference  Lower  Upper  Cohen's d  
TxHxHypertension   Inconsistently Treated-
Never Treated  
 -0.296   -0.870   0.278   -0.284   
  Consistently Treated-Never 
Treated  
 -0.503   -0.945   -0.061   -0.484   
    
Consistently Treated-
Inconsistently Treated  
 -0.207   -0.765   0.350   -0.199   
TxHxLipids   
Inconsistently Treated-
Never Treated  
 -0.131   -0.678   0.416   -0.126   
  Consistently Treated-Never 
Treated  
 0.028   -0.441   0.498   0.027   
    
Consistently Treated-
Inconsistently Treated  








Raw Score Digit Symbol Coding Model 
 
ANCOVA – Raw Score Digit Symbol Coding Model  
Cases  Sum of Squares  df  Mean Square  F  p  η²  η² p  
TxHxHypertension   1676.518   2   838.259   6.490   0.002   0.032   0.042   
TxHxLipids   285.888   2   142.944   1.107   0.332   0.005   0.007   
Age   3913.683   1   3913.683   30.299   < .001   0.075   0.093   
Education   5597.953   1   5597.953   43.338   < .001   0.107   0.128   
Sex at Birth   2645.028   1   2645.028   20.477   < .001   0.051   0.065   
Residuals   37975.769   294   129.169             
Note.  Type III Sum of Squares  
 
Mean Differences Between Groups – Raw Score Digit Symbol Coding Model 
 95% Confidence 
Interval  
 
Variable  Comparison  Difference  Lower  Upper  Cohen's d  
TxHxHypertension   
Inconsistently Treated-
Never Treated  
 -4.044   -10.530   2.441   -0.344   
  Consistently Treated-
Never Treated  
 -7.354   -12.349   -2.359   -0.626   
    
Consistently Treated-
Inconsistently Treated  
 -3.310   -9.606   2.987   -0.282   
TxHxLipids   Inconsistently Treated-
Never Treated  
 -2.129   -8.310   4.053   -0.181   
  Consistently Treated-
Never Treated  
 -0.714   -6.021   4.593   -0.061   
    
Consistently Treated-
Inconsistently Treated  








RBN Verbal Fluency Model 
 
ANOVA – RBN Verbal Fluency Model  
Cases  Sum of Squares  df  Mean Square  F  p  η²  η² p  
TxHxHypertension   0.801   2   0.401   5.008   0.007   0.031   0.031   
TxHxLipids   0.094   2   0.047   0.589   0.556   0.004   0.004   
Residuals   25.126   314   0.080             
Note.  Type III Sum of Squares  
 
Mean Differences Between Groups – RBN Verbal Fluency Model 
 95% Confidence 
Interval  
 
Variable  Comparison  Difference  Lower  Upper  Cohen's d  
TxHxHypertension   Inconsistently Treated-
Never Treated  
 -0.079  -0.229  0.071  -0.279  
  
Consistently Treated-Never 
Treated   -0.117  -0.234  0.001  -0.412  
    
Consistently Treated-
Inconsistently Treated  
 -0.038  -0.184  0.108  -0.133  
TxHxLipids   
Inconsistently Treated-
Never Treated  
 0.048   -0.099   0.194   0.168   
  Consistently Treated-Never 
Treated  
 0.020   -0.105   0.144   0.070   
    
Consistently Treated-
Inconsistently Treated  








Raw Score Verbal Fluency Model 
 
ANCOVA – Raw Score Verbal Fluency Model  
Cases  Sum of Squares  df  Mean Square  F  p  η²  η² p  
TxHxHypertension   890.845   2   445.423   3.180   0.043   0.018   0.020   
TxHxLipids   96.593   2   48.296   0.345   0.709   0.002   0.002   
Age   633.808   1   633.808   4.525   0.034   0.013   0.014   
Education   4575.913   1   4575.913   32.669   < .001   0.092   0.095   
Residuals   43701.509   312   140.069             
Note.  Type III Sum of Squares  
 
Mean Differences Between Groups – Raw Score Verbal Fluency Model 
 95% Confidence 
Interval  
 
Variable  Comparison  Difference  Lower  Upper  Cohen's d  
            
TxHxHypertension   
Inconsistently Treated-




 -3.976  -8.864  0.912  -0.337  
    
Consistently Treated-
Inconsistently Treated  
 -0.870  -6.948  5.208  -0.074  
TxHxLipids   Inconsistently Treated-
Never Treated  
 1.134   -4.956   7.224   0.096   
  Consistently Treated-Never 
Treated  
 1.410   -3.762   6.583   0.120   
    
Consistently Treated-
Inconsistently Treated  








RNB Logical Memory Delayed Free Recall Model 
 
ANOVA – RNB Logical Memory Delayed Free Recall Model  
Cases  Sum of Squares  df  Mean Square  F  p  η²  η² p  
TxHxHypertension   1.001   2   0.500   0.511   0.600   0.003   0.003   
TxHxLipids   0.151   2   0.076   0.077   0.926   4.807e -4   4.822e -4   
Residuals   313.219   320   0.979             
Note.  Type III Sum of Squares  
 
Mean Differences Between Groups – RNB Logical Memory Delayed Free Recall 
Model 
 95% Confidence 
Interval  
 
Variable  Comparison  Difference  Lower  Upper  Cohen's d  
TxHxHypertension   
Inconsistently Treated-
Never Treated  




 -0.126  -0.534  0.281  -0.128  
    Consistently Treated-
Inconsistently Treated  
 -0.097  -0.600  0.406  -0.098  
TxHxLipids   
Inconsistently Treated-
Never Treated  
 0.003   -0.501   0.508   0.003   
  Consistently Treated-Never 
Treated  
 -0.044   -0.472   0.384   -0.045   
    
Consistently Treated-
Inconsistently Treated  








Raw Score Logical Memory Delayed Free Recall Model 
 
ANCOVA – Raw Score Logical Memory Delayed Free Recall Model  
Cases  Sum of Squares  df  Mean Square  F  p  η²  η² p  
TxHxHypertension   2.428   2   1.214   0.098   0.906   5.338e -4   6.207e -4   
TxHxLipids   0.071   2   0.036   0.003   0.997   1.565e -5   1.821e -5   
Age   222.862   1   222.862   18.074   < .001   0.049   0.054   
Education   341.642   1   341.642   27.708   < .001   0.075   0.080   
Sex at Birth   72.145   1   72.145   5.851   0.016   0.016   0.018   
Residuals   3908.673   317   12.330              
Note.  Type III Sum of Squares  
 
Mean Differences Between Groups – Raw Score Logical Memory Delayed Free 
Recall Model 
 95% Confidence 
Interval  
 
Variable  Comparison  Difference  Lower  Upper  Cohen's d  
TxHxHypertension   
Inconsistently Treated-
Never Treated  
 -0.010  -1.846  1.826  -0.003  
  Consistently Treated-Never 
Treated  
 -0.009  -1.451  1.434  -0.002  
    
Consistently Treated-
Inconsistently Treated   0.001  -1.778  1.781  0.000  
TxHxLipids   
Inconsistently Treated-
Never Treated  
 -0.060   -1.847   1.726   -0.017   
  Consistently Treated-Never 
Treated  
 -0.069   -1.585   1.446   -0.020   
    Consistently Treated-
Inconsistently Treated  








RBN Visual Reproduction Delayed Free Recall Model 
 
ANOVA – RBN Visual Reproduction Delayed Free Recall Model  
Cases  Sum of Squares  df  Mean Square  F  p  η²  η² p  
TxHxHypertension   0.954   2   0.477   0.452   0.637   0.003   0.003   
TxHxLipids   2.160   2   1.080   1.022   0.361   0.006   0.006   
Residuals   338.021   320   1.056             
Note.  Type III Sum of Squares  
 
Mean Differences Between Groups – RBN Visual Reproduction Delayed Free 
Recall Model 
 95% Confidence 
Interval  
 
Variable  Comparison  Difference  Lower  Upper  Cohen's d  
TxHxHypertension  
Inconsistently Treated-
Never Treated  




 -0.089  -0.512  0.334  -0.087  
    Consistently Treated-
Inconsistently Treated  
 0.057  -0.468  0.581  0.055  
TxHxLipids   
Inconsistently Treated-
Never Treated  
 -0.161   -0.688   0.365   -0.157   
  Consistently Treated-Never 
Treated  
 -0.194   -0.638   0.250   -0.189   
    
Consistently Treated-
Inconsistently Treated  








Raw Score Visual Reproduction Delayed Free Recall Model 
 
ANCOVA – Raw Score Visual Reproduction Delayed Free Recall Model  
Cases  Sum of Squares  df  Mean Square  F  p  η²  η² p  
TxHxHypertension   4.806   2   2.403   0.337   0.714   0.002   0.002   
TxHxLipids   17.196   2   8.598   1.205   0.301   0.006   0.008   
Age   282.130   1   282.130   39.532   < .001   0.100   0.111   
Education   234.479   1   234.479   32.855   < .001   0.084   0.094   
Residuals   2269.510   318   7.137             
Note.  Type III Sum of Squares  
 
Mean Differences Between Groups – Raw Score Visual Reproduction Delayed Free 
Recall Model 
 95% Confidence 
Interval  
 
Variable  Comparison  Difference  Lower  Upper  Cohen's d  
TxHxHypertension   Inconsistently Treated-
Never Treated  
 -0.146   -1.997   1.705   -0.041   
  Consistently Treated-Never 
Treated  
 -0.213   -1.667   1.241   -0.060   
    
Consistently Treated-
Inconsistently Treated  
 -0.067   -1.861   1.727   -0.019   
TxHxLipids   
Inconsistently Treated-
Never Treated  
 -0.039   -1.840   1.762   -0.011   
  Consistently Treated-Never 
Treated  
 -0.140   -1.667   1.388   -0.040   
    
Consistently Treated-
Inconsistently Treated  









Total Percentage Gray Matter Volume Model 
 
ANCOVA – Total Percentage Gray Matter Volume Model  
Cases  Sum of Squares  df  Mean Square  F  p  η²  η² p  
TxHxHypertension   10.525   2   5.262   1.818   0.164   0.010   0.013   
TxHxLipids   1.075   2   0.537   0.186   0.831   9.855e -4   0.001   
Age   185.736   1   185.736   64.182   < .001   0.170   0.188   
Sex at Birth   88.790   1   88.790   30.682   < .001   0.081   0.099   
Residuals   804.502   278   2.894             
Note.  Type III Sum of Squares  
 
Mean Differences Between Groups – Total Percentage Gray Matter Volume Model 
 95% Confidence 
Interval  
 
Variable  Comparison  Difference  Lower  Upper  Cohen's d  
TxHxHypertension   
Consistently Treated-Never 
Treated  
 -0.430   -1.428   0.568   -0.253   
  Inconsistently Treated-
Never Treated  
 -0.454   -1.191   0.282   -0.267   
    Inconsistently Treated-
Consistently Treated  
 -0.025   -0.996   0.947   -0.014   
TxHxLipids   
Consistently Treated-Never 
Treated  
 -0.084   -0.993   0.825   -0.049   
  Inconsistently Treated-
Never Treated  
 -0.166   -0.935   0.604   -0.097   
    
Inconsistently Treated-
Consistently Treated  









Total Percentage White Matter Volume Model 
 
ANCOVA – Total Percentage White Matter Volume Model  
Cases  Sum of Squares  df  Mean Square  F  p  η²  η² p  
TxHxHypertension   17.159   2   8.579   1.845   0.160   0.011   0.013   
TxHxLipids   7.675   2   3.838   0.825   0.439   0.005   0.006   
Age   236.204   1   236.204   50.794   < .001   0.146   0.154   
Sex at Birth   65.714   1   65.714   14.131   < .001   0.041   0.048   
Residuals   1292.761   278   4.650             
Note.  Type III Sum of Squares  
 
Mean Differences Between Groups – Total Percentage White Matter Volume Model 
 95% Confidence 
Interval  
 
Variable  Comparison  Difference  Lower  Upper  Cohen's d  
TxHxHypertension   
Consistently Treated-Never 
Treated  
 -0.547   -1.812   0.718   -0.254   
  Inconsistently Treated-
Never Treated  
 0.014   -0.920   0.948   0.007   
    Inconsistently Treated-
Consistently Treated  
 0.561   -0.670   1.793   0.260   
TxHxLipids   
Consistently Treated-Never 
Treated  
 0.400   -0.752   1.552   0.186   
  Inconsistently Treated-
Never Treated  
 0.198   -0.777   1.174   0.092   
    
Inconsistently Treated-
Consistently Treated  







Added Variable Plots of Validation Dataset Models 
 












Figure E3. Raw Score Visual Reproduction Delayed Free Recall Added Variable Plot of 





Figure E4. Raw Score BNT Added Variable Plot of TxHxLipids after Accounting for 





Figure E5. RBN Similarities Added Variable Plot of TxHxHypertension after 











Figure E7. Raw Score Similarities Added Variable Plot of TxHxHypertension after 






Figure E8. Raw Score Similarities Added Variable Plot of TxHxLipids after Accounting 





Figure E9. RBN Digit Symbol Coding Added Variable Plot of TxHxHypertension after 






Figure E10. RBN Digit Symbol Coding Added Variable Plot of TxHxLipids after 





Figure E11. Raw Score Digit Symbol Coding Added Variable Plot of TxHxHypertension 






Figure E12. Raw Score Digit Symbol Coding Added Variable Plot of TxHxLipids after 





Figure E13. RBN Verbal Fluency Added Variable Plot of TxHxHypertension after 












Figure E15. Raw Score Verbal Fluency Added Variable Plot of TxHxHypertension after 






Figure E16. Raw Score Verbal Fluency Added Variable Plot of TxHxLipids after 






Figure E17. RBN Logical Memory Delayed Free Recall Added Variable Plot of 






Figure E18. RBN Logical Memory Delayed Free Recall Added Variable Plot of 





Figure E19. Raw Score Logical Memory Delayed Free Recall Added Variable Plot of 






Figure E20. Raw Score Logical Memory Delayed Free Recall Added Variable Plot of 





Figure E21. RBN Visual Reproduction Delayed Free Recall Added Variable Plot of 






Figure E22. RBN Visual Reproduction Delayed Free Recall Added Variable Plot of 







Figure E23. Raw Score Visual Reproduction Delayed Free Recall Added Variable Plot of 







Figure E24. Raw Score Visual Reproduction Delayed Free Recall Added Variable Plot of 






Figure E25. Total Percentage Gray Matter Volume Added Variable Plot of 






Figure E26. Total Percentage Gray Matter Volume Added Variable Plot of TxHxLipids 





Figure E27. Total Percentage White Matter Volume Added Variable Plot of 






Figure E28. Total Percentage White Matter Volume Added Variable Plot of TxHxLipids 
after Accounting for TxHxHypertension and Covariates. 
